Polymeric dyes with deoxyribose-containing linker groups
Polymeric dyes with deoxyribose linker groups address the issue of intramolecular quenching, enhancing brightness and enabling effective visual detection of analyte molecules in aqueous environments.
Patent Information
- Application Number
- JP2020572789
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-06-27
- Filing Date
- 2019-06-27
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-06-27
AI Technical Summary
Existing fluorescent and chromogenic dyes do not achieve the desired enhancement in brightness due to intramolecular fluorescence quenching, limiting their effectiveness in analytical methods, particularly in aqueous environments.
Development of polymeric dyes with deoxyribose linker groups that maintain sufficient spatial separation between fluorescent and chromogenic moieties, reducing or eliminating intramolecular quenching, resulting in increased molar brightness.
The polymeric dyes exhibit enhanced brightness, allowing for strong coloration and fluorescence, enabling effective visual detection of analyte molecules without prior irradiation, and are suitable for various analytical methods.
Smart Images

Figure 0007580689000113 
Figure 0007580689000114 
Figure 0007580689000001
Abstract
Description
[Technical field]
[0001] The present disclosure is generally directed to polymeric fluorescent or chromogenic dyes having deoxyribose linker groups, and methods for their preparation and use in various analytical methods. [Background technology]
[0002] Fluorescent and / or chromogenic dyes are known to be particularly suitable for applications where highly sensitive detection reagents are desired. Dyes capable of preferentially labeling a particular component or constituent in a sample allow researchers to determine the presence, amount and / or location of that particular component or constituent. Furthermore, a particular system can be monitored for its spatial and temporal distribution in a variety of environments. Fluorescence and colorimetric methods have become very widespread in chemistry and biology. These methods provide useful information about the presence, structure, distance, orientation, complex formation and / or location of biomolecules. Furthermore, time-resolved methods are increasingly being used to measure kinetics and rates. As a result, numerous strategies for fluorescent or colorimetric labeling of biomolecules such as nucleic acids and proteins have been developed. Since the analysis of biomolecules is usually carried out in an aqueous environment, emphasis has been placed on the development and use of water-soluble dyes. The use of highly fluorescent or chromogenic dyes is highly desirable because such dyes increase the signal-to-noise ratio and provide other related benefits. Thus, attempts have been made to increase the signal from known fluorescent and / or chromogenic moieties. For example, dimeric and polymeric compounds containing two or more fluorescent and / or chromogenic moieties have been prepared with the expectation that such compounds would result in brighter dyes. However, as a result of intramolecular fluorescence quenching, known dimeric and polymeric dyes do not provide the desired increase in brightness. Summary of the Invention
[0003] Thus, there is a need in the art for dyes with increased molar brightness. Ideally, such dyes and biomarkers should be intensely colored or fluorescent and should be available in a variety of colors and fluorescent wavelengths. The present disclosure fulfills this need and further realizes related advantages. Briefly, embodiments of the present disclosure are generally directed to compounds useful as water-soluble fluorescent and / or chromogenic dyes and / or probes that allow for visual detection of analyte molecules, such as biomolecules, and reagents for their preparation. Methods of visually detecting analyte molecules using the dyes are also described.
[0004] Dye embodiments of the present disclosure may include a linker (e.g., "L 2 ", "L 3 ", "L 4 ", "L 5 " and "L 6 "). In contrast to previous reports of dimeric and / or polymeric dyes, the present dyes are significantly more bright than the corresponding monomeric dye compounds. Without wishing to be bound by theory, it is believed that the linker moiety provides sufficient spatial separation between the fluorescent and / or chromogenic moieties such that intramolecular fluorescence quenching is reduced and / or eliminated. The water-soluble, fluorescent or chromogenic dyes of the present disclosure are highly chromogenic and / or fluorescent and can be easily observed by visual inspection or other means. In some embodiments, the compounds can be observed without prior illumination or chemical or enzymatic activation. By appropriate selection of the dye, a variety of chromogenic visually detectable analyte molecules can be obtained, as described herein. In one embodiment, a compound having the following structure (I):
[0005] [ka] or a stereoisomer, tautomer or salt thereof (wherein R 1, R 2 , R 3 , R 4 , R 5 , L 1a , L 1b , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , M 1 , M 2 , q, w, m and n are as defined herein. The compounds of structure (I) find utility in a number of applications, including use as fluorescent and / or chromogenic dyes in a variety of analytical methods. In another embodiment, a method of staining a sample is provided, comprising adding to said sample a compound of structure (I) in an amount sufficient to produce an optical response when said sample is illuminated with an appropriate wavelength. In yet another embodiment, the present disclosure provides a method for visually detecting an analyte molecule, comprising: (a) providing a compound of structure (I); and (b) detecting said compound by its visible properties. The present invention provides a method comprising: Another disclosed method is a method for visually detecting a biomolecule, comprising: (a) mixing a compound of structure (I) with one or more biomolecules; and (b) detecting said compound by its visible properties. The present invention includes a method comprising the steps of: Another embodiment is a method for visually detecting an analyte, comprising: (a)R 1 or R 2 providing a compound as disclosed herein, wherein the compound comprises a linker comprising a covalent bond to a targeting moiety having specificity for an analyte; (b) mixing the compound and the analyte, thereby causing association of the targeting moiety with the analyte; and (c) detecting said compound by its visible properties. The present invention provides a method comprising: Other embodiments are directed to compositions comprising a compound of structure (I) and one or more analyte molecules, such as biomolecules. Use of such compositions in analytical methods for detecting one or more biomolecules is also provided.
[0006] These and other aspects of the present disclosure will become evident upon reference to the following detailed description. In the drawings, identical reference numbers identify similar elements. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale, and some of these elements have been arbitrarily enlarged and positioned to improve drawing legibility. Furthermore, the particular shapes of the elements as shown are not intended to convey any information regarding the actual shape of the particular elements, but have been selected merely for ease of recognition in the drawings. [Brief description of the drawings]
[0007] [Figure 1] FIG. 1 shows a PAGE gel of compound I-1 and comparative compounds. [Diagram 2] FIG. 1 shows a PAGE gel of compound I-2 and comparative compounds. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the present disclosure. However, it will be understood by those skilled in the art that the present disclosure may be practiced without these details. Unless the context requires otherwise, throughout this specification and claims, the word "comprise" and its variations such as "comprises" and "comprising" are to be interpreted in their open and inclusive sense, i.e., "including but not limited to." Throughout this specification, the references to "one embodiment" or "one embodiment" mean that the particular features, structures, or characteristics described in connection with these embodiments are included in at least one embodiment of the present disclosure. Thus, the appearances of the phrases "in one embodiment" or "in one embodiment" in various places throughout this specification do not necessarily all refer to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0009] "Amino" means -NH 2 Refers to the base. "Carboxy" means -CO 2 Refers to the H group. "Cyano" refers to the group -CN. "Formyl" refers to the group -C(=O)H. "Hydroxy" or "hydroxyl" refers to the group --OH. "Imino" refers to the group =NH. "Nitro" means -NO 2 Refers to the base. "Oxo" refers to the =O substituent. "Sulfhydryl" refers to the -SH group. "Thioxo" refers to the group ═S. "Alkyl" means an alkyl group containing no unsaturation and having 1 to 12 carbon atoms (C 1 -C 12 alkyl), 1 to 8 carbon atoms (C 1 -C 8 alkyl) or 1 to 6 carbon atoms (C 1 -C 6"alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms attached to the remainder of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, etc. Unless specifically stated otherwise in the specification, alkyl groups may be optionally substituted. "Alkylene" or "alkylene chain" refers to a divalent straight or branched hydrocarbon chain, containing no unsaturation and having 1 to 12 carbon atoms, consisting only of carbon and hydrogen, linking the remainder of the molecule to a radical group, e.g., methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, etc. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in this specification, alkylene can be optionally substituted. "Alkenylene" or "alkenylene chain" refers to a divalent straight or branched hydrocarbon chain, consisting solely of carbon and hydrogen, containing at least one carbon-carbon double bond and having 2 to 12 carbon atoms, linking the rest of the molecule to a radical group, e.g., ethenylene, propenylene, n-butenylene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, alkenylene may be optionally substituted. "Alkynylene" or "alkynylene chain" refers to a divalent straight or branched hydrocarbon chain, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond and having 2-12 carbon atoms, linking the rest of the molecule to a radical group, such as ethenylene, propenylene, n-butenylene, and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, alkynylene may be optionally substituted. "Alkyl ether" refers to any alkyl group, as defined above, in which at least one carbon-carbon bond has been replaced by a carbon-oxygen bond. The carbon-oxygen bond may be terminal (as in an alkoxy group) or the carbon-oxygen bond may be internal (i.e., COC). An alkyl ether contains at least one carbon-oxygen bond, but may contain more than one. For example, polyethylene glycol (PEG) is included within the meaning of alkyl ether. Unless otherwise specifically stated herein, alkyl ether groups may be substituted. For example, in some embodiments, an alkyl ether may be an alcohol or -OP(=R a )(R b )R c is replaced by R a , R b and R c are each as defined for compounds of structure (I). "Alkoxy" means a group of the formula -OR a R refers to the group a is an alkyl group, as defined above, containing 1 to 12 carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted. "Alkoxyalkyl ether" means a group of the formula -OR a R b R refers to the group a is an alkylene group as defined above containing 1 to 12 carbon atoms; Rb is an alkyl ether group as defined herein. Unless otherwise specifically stated in the specification, an alkoxyalkyl ether group may be optionally substituted, for example, an alcohol or -OP(=R a )(R b )R c is replaced by R a , R b and R c are each as defined for compounds of structure (I). "Heteroalkyl" refers to an alkyl group, as defined above, that contains at least one heteroatom (e.g., N, O, P, or S) within or at the terminus of the alkyl group. In some embodiments, the heteroatom is present within the alkyl group (i.e., a heteroalkyl contains at least one carbon-[heteroatom] x -carbon bond, x is 1, 2, or 3). In other embodiments, the heteroatom is at the end of the alkyl group, thus serving to attach the alkyl group to the remainder of the molecule (e.g., M1-HA), where M1 is part of the molecule, H is the heteroatom, and A is the alkyl group. Unless otherwise specifically stated herein, heteroalkyl groups may be substituted. Exemplary heteroalkyl groups include ethylene oxide (e.g., polyethylene oxide), which may include a phosphorus-oxygen bond, such as a phosphodiester bond. "Heteroalkoxy" means a heteroalkoxy group of the formula -OR a R refers to the group a is a heteroalkyl group, as defined above, containing 1 to 12 carbon atoms. Unless stated otherwise specifically in the specification, a heteroalkoxy group may be optionally substituted. "Heteroalkylene" refers to an alkylene group as defined above that contains at least one heteroatom (e.g., Si, N, O, P, or S) in the alkylene chain or at the end of the alkylene chain. In some embodiments, the heteroatom is in the alkylene chain (i.e., the heteroalkylene contains at least one carbon-[heteroatom]-carbon bond, and x is 1, 2, or 3). In other embodiments, the heteroatom is at the end of the alkylene, thus serving to bond the alkylene to the remainder of the molecule (e.g., M1-HA-M2, where M1 and M2 are portions of the molecule, H is a heteroatom, and A is an alkylene). Unless otherwise specifically stated herein, the heteroalkylene group may be substituted. Exemplary heteroalkylene groups include ethylene oxide (e.g., polyethylene oxide), as well as the linking groups "C", "HEG", and "PEG 1K" exemplified below.
[0010] [ka] Various embodiments of the heteroalkylene linker include multimers of the above C-linker, HEG linker and / or PEG 1K linker. In some embodiments of the PEG 1K linker, n is in the range of 19 to 25, for example, n is 19, 20, 21, 22, 23, 24 or 25. Multimers can be, for example, of the following structure:
[0011] [ka] (wherein x is 0 or an integer greater than 0, for example, x is in the range of 0 to 100 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). may include. "Heteroalkenylene" is a heteroalkylene, as defined above, containing at least one carbon-carbon double bond. Unless stated otherwise specifically in the specification, a heteroalkenylene group may be optionally substituted. "Heteroalkynylene" is a heteroalkylene containing at least one carbon-carbon triple bond. Unless stated otherwise specifically in the specification, a heteroalkynylene group may be optionally substituted. "Heteroatom" in reference to a "heteroatom linker" refers to a linker group consisting of one or more heteroatoms. Exemplary heteroatom linkers include single atoms selected from the group consisting of O, N, P, and S, as well as multiple heteroatoms, such as those of the formula -P(O - )(=O)O- or -OP(O - )(=O)O-- linkers and multimers, and combinations thereof, are included. "Phosphate" means -OP(=O)(R a )R b Group (R a OH, O - OR c and R b OH, O - , OR c ), a thiophosphate group, or a further phosphate group (R c refers to the counter ion (e.g., Na+, etc.). "Phosphoalkyl" means -OP(=O)(R a )R b R refers to the group a OH, O - OR c and R b is -Oalkyl, and R c is the counter ion (e.g., Na + Unless otherwise specifically stated herein, a phosphoalkyl group may be substituted. For example, in certain embodiments, the -Oalkyl portion in a phosphoalkyl group is hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether, thiophosphoalkylether, or -OP(=R a )(R b )R c and R a , R b and Rc are each as defined for compounds of structure (I). "Phosphoalkyl ether" means -OP(=O)(R a )R b R refers to the group a OH, O - OR c and R b is -O alkyl ether, R c is a counterion (e.g., Na+, etc.). Unless otherwise specifically stated herein, a phosphoalkyl ether group may be substituted. For example, in certain embodiments, the -O alkyl ether moiety in a phosphoalkyl ether group is hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, thiophosphoalkyl ether, or -OP(=R a )(R b )R c and R a , R b and R c are each as defined for compounds of structure (I). What is "thiophosphate"? 、 -OP(=R a )(R b )R c R refers to the group a is O or S, and R b OH, O - , S - , OR d or S.R. d and R c OH, SH, O - , S - , OR d , S.R. d , a phosphate group, or a further thiophosphate group, and R d is a counter ion (e.g., Na+), where i) R a is S, ii) R b is S - Or SR d iii) Rc , SH, S - Or SR d or iv) any combination of i), ii) and / or iii). "Thiophosphoalkyl" means -OP(=R a )(R b )R c R refers to the group a is O or S, and R b OH, O - , S - , OR d or S.R. d and R c is -Oalkyl, and R d is a counter ion (e.g., Na+), where i) R a is S, ii) R b is S - Or SR d or iii) R a is S and R b is S - Or SR d Unless otherwise specifically stated herein, a thiophosphoalkyl group may be optionally substituted. For example, in certain embodiments, the -Oalkyl portion in a thiophosphoalkyl group is hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether, thiophosphoalkylether, or -OP(=R a )(R b )R c and R a , R b and R c are each as defined for compounds of structure (I). "Thiophosphoalkyl ether" means -OP(=R a )(R b )R c R refers to the group a is O or S, and R b OH, O - , S - , ORd or S.R. d and R c is -O alkyl ether, R d is a counter ion (e.g., Na+), where i) R a is S, ii) R b is S - Or SR d or iii) R a is S and R b is S - Or SR d Unless otherwise specifically stated herein, a thiophosphoalkyl ether group may be optionally substituted. For example, in certain embodiments, the -O alkyl ether moiety in a thiophosphoalkyl group may be hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, thiophosphoalkyl ether, or -OP(=R a )(R b )R c and R a , R b and R c are each as defined for compounds of structure (I). "Carbocyclic" refers to a stable 3- to 18-membered aromatic or non-aromatic ring containing 3 to 18 carbon atoms. Unless otherwise specifically stated herein, carbocyclic rings can be monocyclic, bicyclic, tricyclic or tetracyclic ring systems, which may include fused or bridged ring systems and may be partially or fully saturated. Non-aromatic carbocyclyl radicals include cycloalkyl, while aromatic carbocyclyl radicals include aryl. Unless otherwise specifically stated herein, carbocyclic groups may be substituted. "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic carbocyclic ring, which may include saturated or unsaturated fused or bridged ring systems having 3 to 15 carbon atoms, preferably 3 to 10 carbon atoms, and which is attached to the remainder of the molecule by a single bond. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo-[2.2.1]heptanyl, and the like. Unless otherwise specifically stated herein, cycloalkyl groups may be substituted. "Aryl" refers to a ring system containing at least one carbocyclic aromatic ring. In some embodiments, an aryl contains 6 to 18 carbon atoms. The aryl ring may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused or bridged ring systems. Aryl includes, but is not limited to, aryl derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless otherwise specifically stated herein, an aryl group may be substituted.
[0012] "Heterocyclic" refers to a stable 3-18 membered aromatic or non-aromatic ring containing 1-12 carbon atoms and 1-6 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless otherwise specifically stated herein, a heterocyclic ring may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems, and the nitrogen, carbon or sulfur atoms in the heterocyclic ring may be oxidized. The nitrogen atom may be quaternized. The heterocyclic ring may be partially or fully saturated. Examples of aromatic heterocyclic rings are listed below in the definition of heteroaryl (i.e., heteroaryl is a subset of heterocyclic). Examples of non-aromatic heterocyclic rings include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, pyrazolopyrimidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trioxanyl, trithianyl, triazinanyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, a heterocyclic group may be optionally substituted. "Heteroaryl" refers to a 5-14 membered ring system containing 1-13 carbon atoms, 1-6 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring. For purposes of certain embodiments of the present disclosure, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems, and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized and the nitrogen atom may be optionally quaternized.Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzoindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofurano ... Nonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, benzoxazolinonyl, benzimidazolethionyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxa Zolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, pteridinonyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyridinonyl, pyrazinyl, pyrimidinyl, pyrimidinonyl ( pryrimidinonyl), pyridazinyl, pyrrolyl, pyrido[2,3-d]pyrimidinonyl, quinazolinyl, quinazolinonyl, quinoxalinyl, quinoxalinonyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, thieno[3,2-d]pyrimidin-4-onyl, thieno[2,3-d]pyrimidin-4-onyl, triazolyl, tetrazolyl, triazinyl and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, heteroaryl groups are optionally substituted.
[0013] The suffix "-ene" refers to a particular structural feature (e.g., alkyl, aryl, heteroalkyl, heteroaryl) that is attached to the rest of the molecule through a single bond and to the radical group through a single bond. In other words, the suffix "-ene" refers to a linker that has the structural feature of the moiety to which it is attached. The point of attachment of the "-ene" chain to the rest of the molecule and to the radical group can be through one atom of any two atoms in the chain, or through any two atoms in the chain. For example, heteroarylene refers to a linker that includes a heteroaryl moiety as defined herein. "Fused" refers to a ring system that includes at least two rings, where the two rings share at least one common ring atom, e.g., two common ring atoms. When the fused ring is a heterocyclyl or heteroaryl ring, the common ring atom can be carbon or nitrogen. Fused rings include bicyclic, tricyclic, tertracyclic, and the like.
[0014] As used herein, the term "substituted" refers to any of the above groups (e.g., alkyl, alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene, alkoxy, alkyl ether, phosphoalkyl, phosphoalkyl ether, thiophosphoalkyl, thiophosphoalkyl ether, carbocyclic, cycloalkyl, aryl, heterocyclic, and / or heteroaryl) in which at least one hydrogen atom (e.g., one, two, three, or all of the hydrogen atoms) is replaced with a halogen atom, such as F, Cl, Br, and I; a hydroxyl atom, such as aryl, ... The term "substituted" also refers to any of the above groups in which one or more hydrogen atoms are replaced by a bond to a non-hydrogen atom, such as an oxygen atom in groups such as alkoxy groups, ester groups, sulfur atoms in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups, nitrogen atoms in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines, silicon atoms in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups, and other heteroatoms in various other groups. "Substituted" also refers to any of the above groups in which one or more hydrogen atoms are replaced by a higher bond (e.g., a double bond or a triple bond) to a heteroatom, such as an oxygen in oxo groups, carbonyl groups, carboxyl groups, and ester groups, and a nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, "substituted" includes any of the above groups in which one or more hydrogen atoms are replaced by a bond to a heteroatom, such as an oxygen in an oxo group, a carbonyl group, a carboxyl group, and an ester group, and a nitrogen in groups such as an imine, an oxime, a hydrazone, and a nitrile. g R h , -NR g C(=O)R h , -NR g C(=O)NR g R h , -NR g C(=O)OR h , -NR g SO 2 R h , -OC(=O)NR g R h , -OR g , -SR g , -SOR g , -SO2 R g , -OSO 2 R g , -SO 2 OR g , =NSO 2 R g and -SO 2 NR g R h "Substituted" also includes any of the above groups, wherein one or more hydrogen atoms are replaced by -C(=O)R. g , -C(=O)OR g , -C(=O)NR g R h , -CH 2 SO 2 R g , -CH 2 SO 2 NR g R h In the above, R g and R h are the same or different and are independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroarylalkyl. "Substituted" further refers to any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroarylalkyl group. Additionally, any of the above-mentioned substituents may also be substituted with one or more of the above-mentioned substituents.
[0015] "Conjugation" refers to the overlap of one p orbital with another p orbital across an intervening sigma bond. Conjugation can occur in cyclic or acyclic compounds. "Degree of conjugation" refers to the overlap of at least one p orbital with another p orbital across an intervening sigma bond. For example, 1,3-butadiene has one degree of conjugation, while benzene and other aromatic compounds usually have multiple degrees of conjugation. Fluorescent and chromogenic compounds usually contain at least one degree of conjugation. "Fluorescent" refers to a molecule that can absorb light of a particular frequency and emit light of a different frequency. Fluorescence is well known to those of skill in the art. "Chromogenic" refers to molecules that absorb light within the colored spectrum (i.e., red, yellow, blue, etc.). "Linker" refers to a continuous chain of at least one atom, such as carbon, oxygen, nitrogen, sulfur, phosphorus, and combinations thereof, that connects one portion of a molecule to another portion of the same molecule, or to a different molecule, moiety, or solid support (e.g., a microparticle). The linker can be linked to the molecule through a covalent bond or other means, such as ionic or hydrogen bonding interactions.
[0016] The term "biomolecule" refers to any of a variety of biological substances, including nucleic acids, carbohydrates, amino acids, polypeptides, glycoproteins, hormones, aptamers, and mixtures thereof. More specifically, the term is intended to include, but is not limited to, RNA, DNA, oligonucleotides, modified or derivatized nucleotides, enzymes, receptors, prions, receptor ligands (including hormones), antibodies, antigens, and toxins, as well as bacteria, viruses, blood cells, and tissue cells. The visually detectable biomolecules of the present disclosure (e.g., compounds of structure (I) having a biomolecule linked to a compound of structure (I)) are prepared by contacting a biomolecule with a compound having a reactive group that allows the biomolecule to be bound to the compound via any available atom or functional group, such as amino, hydroxyl, carboxyl, or sulfhydryl groups on the biomolecule, as further described herein.
[0017] A "reactive group" is a moiety that can react with a second reactive group (e.g., a "complementary reactive group") to form one or more covalent bonds, for example, by substitution, oxidation, reduction, addition, or cycloaddition reactions. Exemplary reactive groups are provided in Table 1 and include, for example, nucleophiles, electrophiles, dienes, dienophiles, aldehydes, oximes, hydrazones, alkynes, amines, azides, acyl azides, acyl halides, nitriles, nitrones, sulfhydryls, disulfides, sulfonyl halides, isothiocyanates, imidoesters, activated esters, ketones, α,β-unsaturated carbonyls, alkenes, maleimides, α-haloimides, epoxides, aziridines, tetrazines, tetrazoles, phosphines, biotins, thiiranes, and the like.
[0018] "Bio-conjugation" or "bio-conjugate" and related variants refer to a chemical reaction strategy for forming a stable covalent bond between two molecules. The term "bio-conjugate" is commonly used when one of the molecules is a biological molecule (e.g., an antibody), but can be used to describe forming a covalent bond with a non-biological molecule (e.g., a polymeric resin). The product or compound derived from such a reaction strategy is a "conjugate," "bioconjugate," or grammatical equivalent. The terms "visible" and "visually detectable" are used herein to refer to substances observable by visual inspection without prior illumination or chemical or enzymatic activation. Such visually detectable substances absorb and emit light in the spectral region ranging from about 300 to about 900 nm. Preferably, such substances are strongly colored, preferably with a chromaticity of at least about 40,000, more preferably at least about 50,000 M, even more preferably at least about 60,000, even more preferably at least about 70,000, and most preferably at least about 80,000 M. -1 cm -1The compounds of the present disclosure can be detected by naked eye observation or by using optical-based detection devices, including, but not limited to, absorption spectrophotometers, transmitted light microscopes, digital cameras and scanners. Visually detectable substances are not limited to those that emit and / or absorb light in the visible spectrum. Substances that emit and / or absorb light in the ultraviolet (UV) region (about 10 nm to about 400 nm), infrared (IR) region (about 700 nm to about 1 mm), and substances that emit and / or absorb in other regions of the electromagnetic spectrum are also included within the scope of "visually detectable" substances.
[0019] For the purpose of the present disclosure, the term "photostable visible dye" refers to a chemical moiety that is visually detectable and does not significantly change or decompose when exposed to light, as defined herein above.Preferably, the photostable visible dye does not show significant decolorization or decomposition after exposure to light for at least 1 hour.More preferably, the visible dye is stable after exposure to light for at least 12 hours, even more preferably at least 24 hours, even more preferably at least 1 week, and most preferably at least 1 month.Non-limiting examples of photostable visible dyes suitable for use in the compounds and methods of the present disclosure include azo dyes, thioindigo dyes, quinacridone pigments, dioxazines, phthalocyanines, perinones, diketopyrrolopyrroles, quinophthalones, and triarylcarboniums.
[0020] As used herein, the term "perylene derivative" is intended to include any substituted perylene that is visually detectable. However, the term is not intended to include perylene itself. The terms "anthracene derivative", "naphthalene derivative", and "pyrene derivative" are used analogously. In some preferred embodiments, the derivative (e.g., perylene, pyrene, anthracene, or naphthalene derivative) is an imide, bisimide, or hydrazamimide derivative of perylene, anthracene, naphthalene, or pyrene.
[0021] The visually detectable molecules of various embodiments of the present disclosure are useful for a wide range of analytical applications, such as biochemical and biomedical applications, where it is necessary to determine the presence, location or amount of a particular analyte (e.g., a biomolecule). Thus, in another aspect, the present disclosure provides a method for visually detecting a biomolecule, comprising: (a) providing a biological system with a visually detectable biomolecule comprising a compound of structure (I) linked to the biomolecule; and (b) detecting the biomolecule by its visual characteristics. For the purposes of the present disclosure, the phrase "detecting a biomolecule by its visual characteristics" means that the biomolecule is observed by the naked eye, or with an optical-based detection device, including, but not limited to, an absorption spectrophotometer, a transmitted light microscope, a digital camera and a scanner, without illumination or chemical or enzymatic activation. Densitometers can be used to quantify the amount of visually detectable biomolecules present. For example, the relative amounts of biomolecules in two samples can be determined by measuring the relative optical density. If the stoichiometry of dye molecules per biomolecule is known and the extinction coefficient of the dye molecule is known, the absolute concentration of the biomolecule can also be determined from the optical density measurement.As used herein, the term "biological system" is used to refer to any solution or mixture that contains one or more biomolecules in addition to visually detectable biomolecules.Non-limiting examples of such biological systems include cells, cell extracts, tissue samples, electrophoretic gels, assay mixtures, and hybridization reaction mixtures.
[0022] "Solid support" or "solid support moiety" refers to any solid substrate known in the art for supporting molecules on a solid phase, for example, "microparticle" refers to any of a number of small particles useful for binding to compounds of the present disclosure, including, but not limited to, glass beads, magnetic beads, polymeric beads, non-polymeric beads, etc. In certain embodiments, the microparticle comprises a polystyrene bead.
[0023] A "targeting moiety" is a moiety that selectively binds to or associates with a particular target, such as an analyte molecule. "Selectively" binds or associates means that the targeting moiety preferentially associates or binds to a desired target over other targets. In some embodiments, the compounds disclosed herein include a linking group to the targeting moiety to selectively bind or associate the compound with the analyte of interest (i.e., the target of the targeting moiety), thus allowing detection of the analyte. Exemplary targeting moieties include, but are not limited to, antibodies, antigens, nucleic acid sequences, enzymes, proteins, cell surface receptor antagonists, and the like. In some embodiments, the targeting moiety is a moiety, such as an antibody, that selectively binds to or associates with a target feature on or in a cell, such as a target feature on the cell membrane or other structural surface of the cell, thus allowing detection of the cell of interest. Small molecules that selectively bind to or associate with a desired analyte are also contemplated as targeting moieties in certain embodiments. Those skilled in the art will recognize other analytes and corresponding targeting moieties that are useful in various embodiments. "Base pairing moiety" refers to a heterocyclic moiety that can hybridize with a complementary heterocyclic moiety through hydrogen bonds (e.g., Watson-Crick base pairing). Base pairing moieties include natural and unnatural bases. Non-limiting examples of base pairing moieties are RNA and DNA bases such as adenosine, guanosine, thymidine, cytosine and uridine, and their analogs. The embodiments of the present disclosure disclosed herein are also intended to encompass all compounds that are isotopically labeled by replacing one or more atoms with atoms having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include, respectively: 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O.31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I and 125 These include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as I. Isotopically labeled compounds of structure (I) can generally be prepared by conventional techniques known to those of skill in the art, or by methods analogous to those described below and in the Examples below, substituting an appropriate isotopically labeled reagent in place of a previously used non-labeled reagent.
[0024] "Stable compound" and "stable structure" are intended to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
[0025] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where said event or circumstance occurs as well as cases where it does not occur. For example, "optionally substituted alkyl" means that the alkyl group may be substituted or unsubstituted, and that the description includes both substituted and unsubstituted alkyl groups. "Salt" includes both acid addition salts and base addition salts. "Acid addition salts" include salts of inorganic acids, such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and salts of acids, such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, schizoic acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, and glutamic acid. It refers to salts formed with organic acids such as taric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenic acid.
[0026] "Base addition salts" refers to salts prepared from the addition of inorganic or organic bases to free acids. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
[0027] Crystallization may produce solvates of the compounds described herein. The embodiments of the present disclosure include all solvates of the compounds described. As used herein, the term "solvate" refers to an aggregate that includes one or more molecules of the compounds of the present disclosure and one or more molecules of a solvent. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present disclosure may exist as hydrates, including monohydrates, dihydrates, hemihydrates, sesquihydrates, trihydrates, tetrahydrates, etc., as well as corresponding solvate forms. The compounds of the present disclosure may be true solvates, while in other cases, the compounds of the present disclosure may simply retain incidental water or another solvent, or may be a mixture of water and some incidental solvent.
[0028] The disclosed compounds (e.g., compounds of structure I), or salts, tautomers, or solvates thereof, may contain one or more asymmetric centers and may therefore give rise to enantiomers, diastereomers, and other stereoisomers that may be defined in terms of absolute stereochemistry as (R)- or (S)-, or, in the case of amino acids, (D)- or (L)-. The disclosed embodiments are intended to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of the racemates (or racemates of salts or derivatives) using, for example, chiral high performance liquid chromatography (HPLC). Where the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, the compounds are intended to include both E and Z geometric isomers, as well as all tautomers.
[0029] "Stereoisomers" refer to compounds composed of identical atoms joined by the same bonds but with different three-dimensional structures that cannot be interconverted. The present disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another. "Tautomer" refers to a proton transfer from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any of the above compounds. Various tautomers of the compounds can be easily derived by one skilled in the art. The chemical naming protocol and structure diagrams used herein are a modification of the IUPAC nomenclature system using the ACD / Nomenclature version 9.07 software program and / or the ChemDraw Ultra version 11.0 software naming program (CambridgeSoft). Common names familiar to those skilled in the art are also used.
[0030] As mentioned above, in one embodiment of the present disclosure, compounds are provided that are useful as fluorescent and / or chromogenic dyes in various analytical methods. In other embodiments, compounds are provided that are useful as synthetic intermediates for preparing compounds that are useful as fluorescent and / or chromogenic dyes. In general terms, embodiments of the present disclosure are directed to dimeric or higher polymers of fluorescent and / or chromogenic moieties. The fluorescent and / or chromogenic moieties are linked by a linking moiety. Without wishing to be bound by theory, it is believed that the linker helps to maintain sufficient spatial distance between the fluorescent and / or chromogenic moieties, thus reducing or eliminating intramolecular quenching, thus resulting in dye compounds with high molar "brightness" (e.g., high fluorescence emission).
[0031] Thus, in some embodiments, the compound has the following structure (A): [ka] (A) where L is one or more (e.g., each) M 1 is a linker (e.g., heteroalkylene) sufficient to maintain spatial separation between the R groups, such that intramolecular quenching is reduced or eliminated; 1 , R 2 , L 1a , L 1b , L 2 , L 3 and n is as defined for structure (I). In some embodiments of structure (A), L is a linker that includes one or more ethylene glycol or polyethylene glycol moieties.
[0032] In another embodiment, a compound having the following structure (I): [ka] or a stereoisomer, salt or tautomer thereof, M 1 and M. 2 is, independently at each occurrence, a moiety that contains a chromophore, L 1a is, independently at each occurrence, a heteroarylene linker; L 1b , L 2 , L 3 , L 5 , L 6 and L 7 is independently at each occurrence an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; L 4 is independently at each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; R 1 and R 2 are each independently H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, -OP(=R a )(R b )R c , Q or a protected form thereof, or L′; R 3 is independently at each occurrence H, alkyl or alkoxy; R 4 are independently selected for each occurrence: OH, SH, O - , S - , OR d or S.R. d and R 5 is independently at each occurrence oxo, thioxo, or absent; R a is O or S, R b OH, SH, O- , S - , OR d or S.R. d and R c OH, SH, O - , S - , OR d , O.L.', S.R. d , alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, or thiophosphoalkyl ether; R d is the counter ion, Q is, independently at each occurrence, a moiety that contains a reactive group or a protected form thereof that is capable of forming a covalent bond with an analyte molecule, a targeting moiety, a solid support, or a complementary reactive group Q'; L' is, independently at each occurrence, a linker that includes a covalent bond to Q, a linker that includes a covalent bond to a targeting moiety, a linker that includes a covalent bond to an analyte molecule, a linker that includes a covalent bond to a solid support, a linker that includes a covalent bond to a solid support moiety, a linker that includes a covalent bond to a nucleoside, or a linker that includes a covalent bond to an additional compound of structure (I); m, for each occurrence, is an integer greater than or equal to 1; n is an integer equal to or greater than 1, q and w are, independently at each occurrence, 0 or 1, provided that at least one occurrence of w is 1. is provided.
[0033] Various linkers and substituents in the compounds of structure (I), such as M 1 , M 2 , Q, R 1 , R 2 , R 3 , R c , L 1a , L 1b , L 2 , L 3 , L 4 , L 5 , L 6and L 7 ) may be substituted with one more substituent. For example, in some embodiments, the optional substituents are selected to optimize the aqueous solubility or other properties of the compounds of structure (I). In certain embodiments, the chromophore, alkyl, alkoxy, alkyl ether, heteroarylene, heteroalkyl, alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene, alkoxyalkyl ether, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, and thiophosphoalkyl ether in the compounds of structure (I) may each be substituted with one more substituent selected from the group consisting of hydroxyl, alkoxy, alkyl ether, alkoxyalkyl ether, sulfhydryl, amino, alkylamino, carboxyl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, and thiophosphoalkyl ether. In certain embodiments, the optional substituent is -OP(=Ra)(Rb)Rc, where Ra, Rb, and Rc are as defined for the compounds of structure (I).
[0034] In some embodiments, the occurring L 1a At least one of L is an optionally substituted 5- to 7-membered heteroarylene linker. 1a is, independently at each occurrence, an optionally substituted 5- to 7-membered heteroarylene linker. In some embodiments, L 1a is a 6-membered heteroarylene. 1a contains two N atoms and two O atoms. In certain embodiments, L 1a is replaced at each occurrence. In some related embodiments, L 1b is substituted, e.g., L 1b is substituted with oxo, alkyl (e.g., methyl, ethyl, etc.), or combinations thereof. In more specific embodiments, L 1a In some embodiments, each occurrence of L is substituted with at least one oxo.1a has the following structure: [ka] has one of the following:
[0035] In some embodiments, L 1b independently at each occurrence represents an optionally used alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene, alkyleneheteroarylenealkylene, alkyleneheterocyclylenealkylene, alkylenecarbocyclylenealkylene, heteroalkyleneheteroarylenealkylene, heteroalkyleneheterocyclylenealkylene, heteroalkylenecarbocyclylenealkylene, heteroalkyleneheteroaryleneheteroalkylene, heteroalkyleneheterocyclyleneheteroalkylene, heteroalkylenecarbocyclyleneheteroalkylene In some embodiments, L is an alkylene, an alkyleneheteroarylene, an alkyleneheterocyclyleneheteroalkylene, an alkylenecarbocyclyleneheteroalkylene, a heteroarylene, a heterocyclylene, a carbocyclylene, an alkyleneheteroarylene, an alkyleneheterocyclylene, a heteroarylenealkylene, an alkylenecarbocyclylene, a carbocyclylenealkylene, a heteroalkyleneheteroarylene, a heteroalkyleneheterocyclylene, a heteroaryleneheteroalkylene, a heteroalkylenecarbocyclylene, a carbocyclyleneheteroalkylene, or a heteroatom linker. 1b is an optionally substituted heteroalkenylene linker.
[0036] In some embodiments, the occurring L 1b At least one of L is substituted. 1b is replaced for each occurrence. In some more specific embodiments, L 1b is substituted by oxo. In another embodiment, L 1bis, independently at each occurrence, a linker that includes a functional group that can be formed by reaction of two complementary reactive groups (eg, triazolyl, amide, etc.), such as Q groups.
[0037] Optional linker L 1b and L 7 is the M to the remainder of the compound 1 Part and M 2 For example, in some embodiments, a synthetic precursor to a compound of structure (I) is prepared, and M 1 and M. 2 The moieties are attached to the synthetic precursors using any number of facile methods known in the art, such as the method known as "click chemistry." For this purpose, any rapid and substantially irreversible reaction can be used to attach M to the synthetic precursors to form the compounds of structure (I). 1 and M. 2 can be coupled. Exemplary reactions include copper-catalyzed reactions of azides with alkynes to form triazoles (Huisgen 1,3-dipolar cycloaddition), reactions of dienes with dienophiles (Diels-Alder), strain-promoted alkyne-nitrone cycloaddition, strain-promoted cycloalkyne-azide cycloaddition (Cu-free click), reactions of strained alkenes with azides, tetrazines or tetrazoles, [3+2] cycloadditions of alkenes with azides, inverse demand Diels-Alder of alkenes with tetrazines, photoreactions of alkenes with tetrazoles, as well as various substitution reactions such as replacement of leaving groups by nucleophilic attack on an electrophilic atom. Exemplary substitution reactions include reactions of amines with activated esters; N-hydroxysuccinimide esters; isocyanates; isothiocyanates, and the like. In some embodiments, L 1b or L 7 The reaction to form may be carried out in an aqueous environment.
[0038] Thus, in some embodiments, L 1b or L 7is, independently at each occurrence, a linker that includes a functional group formable by reaction of two complementary reactive groups, e.g., a functional group that is the product of one of the "click" reactions described above. In various embodiments, L 1b or L 7 occurs, the functional group may be formed by reaction of an aldehyde, oxime, hydrazone, alkyne, amine, azide, acyl azide, acyl halide, nitrile, nitrone, sulfhydryl, disulfide, sulfonyl halide, isothiocyanate, imido ester, activated ester (e.g., N-hydroxysuccinimide ester), ketone, α,β-unsaturated carbonyl, alkene, maleimide, α-haloimide, epoxide, aziridine, tetrazine, tetrazole, phosphine, biotin, or thiirane functional group with a complementary reactive group, for example, reaction of an amine with an N-hydroxysuccinimide ester or an isothiocyanate.
[0039] In another embodiment, L 1b or L 7 When at least one occurrence of L occurs, the functional group may be formed by reaction of an alkyne and an azide. 1b or L 7 When at least one occurrence of is present, the functional group can be formed by reaction of an amine (eg, a primary amine) and an N-hydroxysuccinimide ester or isothiocyanate. In more embodiments, the L 1b or L 7 For at least one of L, the functional group comprises an alkene, ester, amide, thioester, disulfide, carbocyclic, heterocyclic, or heteroaryl group. 1b or L 7 When at least one occurrence of L occurs, the functional group comprises an alkene, ester, amide, thioester, thiourea, disulfide, carbocyclic, heterocyclic, or heteroaryl group. In other embodiments, the functional group comprises an amide or thiourea. In some more specific embodiments, L 1b or L 7occurs at least once, L 1b or L 7 is a linker that includes a triazolyl functional group. In some related embodiments, L 1b or L 7 In another embodiment, L 1b or L 7 At least one occurrence of is a linker that includes an amide or thiourea functionality.
[0040] In yet another embodiment, the L 1b For at least one of 1b -M has the following structure: [ka] (In the formula, L 1c and L 1d are each independently an optional linker.
[0041] In a different embodiment, the L 1b For at least one of 1b -M has the following structure: [ka] (In the formula, L 1c and L 1d are each independently an optional linker. In the various embodiments described above, L 1c Or L 1d , or both are absent. 1c Or L 1d , or both are present.
[0042] In some embodiments, L 1c and L 1d Each occurrence, if any, is independently alkylene or heteroalkylene. For example, in some embodiments, L 1c and L 1dis, if present, independently one of the following structures: [ka] has.
[0043] In yet another embodiment, L 7 occurs at least once, L 7 -M 2 has the following structure: [ka] (In the formula, L 1e and L 1f are each independently an optional linker has.
[0044] In a different embodiment, L 7 occurs at least once, L 7 -M 2 has the following structure: [ka] (In the formula, L 1e and L 1f are each independently an optional linker has. In the various embodiments described above, L 1e Or L 1f , or both are absent. 1e Or L 1f , or both are present.
[0045] In some embodiments, L 1e and L 1f Each occurrence, if any, is independently alkylene or heteroalkylene. For example, in some embodiments, L 1c and L 1f may, when present, independently have the structure: [ka] has one of the following:
[0046] In some embodiments, the occurring L 1b At least one of the following structures: [ka] (In the formula, a, b, and c are each independently an integer ranging from 1 to 6. has one of the following:
[0047] In some embodiments, L 1b Each occurrence of has the following structure: [ka] (In the formula, a, b, and c are each independently an integer ranging from 1 to 6. has one of the following:
[0048] In some embodiments, the occurring L 1b At least one of the following structures: [ka] has one of the following:
[0049] In yet another alternative embodiment of structure (I), L 1b is, independently at each occurrence, an optional alkylene or heteroalkylene linker. In certain embodiments, L 1b is one of the following structures: [ka] has.
[0050] In yet another alternative embodiment of structure (I), L 7 is, independently at each occurrence, an optional alkylene or heteroalkylene linker. In certain embodiments, L 7is one of the following structures: [ka] has.
[0051] In some embodiments, the occurring L 3 At least one of L is an alkylene linker. 3 is an alkylene linker at each occurrence. In certain embodiments, the alkylene linker is a methylene linker. In some embodiments, the occurring L 2 In a more specific embodiment, at least one of L 2 does not exist for each occurrence. In certain embodiments, the occurring L 5 or L 6 At least one of L is a heteroalkylene linker. 5 or L 6 Each occurrence of L is a heteroalkylene linker. 4 In some embodiments, at least one of the occurrences of L 5 or L 6 At least one of the L's comprises an alkylene oxide. In some of the above embodiments, the alkylene oxide is ethylene oxide, e.g., polyethylene oxide. In certain embodiments, the L 5 or L 6 At least one of L is an alkylene linker (e.g., methylene). 5 or L 6 Each occurrence of is an alkylene linker (e.g., methylene). In certain embodiments, the occurring L 5 At least one of L is a heteroalkylene linker. 5 Each occurrence of L is a heteroalkylene linker. 5At least one of the occurrences of L 5 At least one of L is an alkylene linker (e.g., methylene). 5 Each occurrence of L is an alkylene linker (e.g., methylene). 5 In some more specific embodiments, at least one of L 5 does not exist for each occurrence. In certain embodiments, the occurring L 6 At least one of L is a heteroalkylene linker. 6 Each occurrence of L is a heteroalkylene linker. 6 At least one of the L's comprises an alkylene oxide. In some of the above embodiments, the alkylene oxide is ethylene oxide, e.g., polyethylene oxide. In certain embodiments, the L 6 At least one of L is an alkylene linker (e.g., methylene). 6 Each occurrence of L is an alkylene linker (e.g., methylene). 6 In some more specific embodiments, at least one of L 6 does not exist for each occurrence. In certain embodiments, the occurring L 5 or L 6 In a more specific embodiment, at least one of L 5 or L 6 Each occurrence of L contains a phosphodiester moiety. 2 , L 3 , L 4 or L 6 is expressed independently for each occurrence as C 1 -C 6 Alkylene, C 2 -C 6Alkenylene or C 2 -C 6 It is alkynylene.
[0052] In some embodiments, the occurring L 5 At least one of L is heteroalkylene. 5 Each occurrence represents a heteroalkylene, for example the structure: [ka] and heteroalkylene including one of the following.
[0053] In some embodiments, the occurring L 6 At least one of L is heteroalkylene. 6 Each occurrence represents a heteroalkylene, for example the structure: [ka] and heteroalkylene including one of the following.
[0054] In some of the above embodiments, heteroalkylene (e.g., L 3 , L 4 , L 5 or L 6 ) has the following structure: [ka] wherein z is an integer ranging from 19 to 30. In some embodiments, Z is in the range of 19 to 28. In certain embodiments, the average of z is 23. In some embodiments, the average of z is 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28. In some embodiments, the R 3 is H. In more specific embodiments, at least one of R 3 For each occurrence, H.
[0055] In some embodiments, m is 0. In some of the above embodiments, q is 0. In some related embodiments, the compound has the following structure (Ia): [ka] has.
[0056] In some other embodiments, the compound has one of the following structures (Ib) or (Ic): [ka] (In the formula, L 1b is independently at each occurrence an optionally substituted alkylene or an optionally substituted heteroalkylene linker. has.
[0057] In some embodiments, the compound has one of the following structures (Id) or (Ie): [ka] (In the formula, and z is an integer from 1 to 100. 1b independently at each occurrence, contains an amide functionality or a triazolyl functionality.
[0058] In still other embodiments of any of the compounds of structure (I), R 5 are independently expressed as OH, O - OR d "OR d " and "SR d " is O with a cation - and S - For example, the disodium salt of a phosphate group can be represented as follows: [ka] (In the formula, R d is sodium (Na+ ) is.
[0059] In other embodiments of any of the compounds of structure (I), any occurrence of R 4 At least one of R is oxo. In other embodiments of any of the compounds of structure (I), R 4 Each occurrence of is oxo. In various other embodiments, R 1 and R 2 are each independently OH or -OP(=R a )(R b )R c In some different embodiments, R 1 or R 2 is OH or -OP(=R a )(R b )R c and R 1 or R 2 The other is Q or a linker that comprises a covalent bond to Q. In yet another embodiment of any of the compounds of structure (I) above, R 1 and R 2 are each independently -OP(=R a )(R b )R c In some of these embodiments, R c is OL'. In other embodiments, R 1 and R 2 are each independently -OP(=R a )(R b ) OL', where L' is an alkylene or heteroalkylene linker to Q, a targeting moiety, an analyte (e.g., an analyte molecule), a solid support, a solid support moiety, a nucleoside, or an additional compound of structure (I).
[0060] The linker L' can be any linker suitable for linking Q, a targeting moiety, an analyte (e.g., an analyte molecule), a solid support, a solid support residue, a nucleoside, or an additional compound of structure (I) to the compound of structure (I). Advantageously, certain embodiments include the use of an L' moiety that is selected to increase or optimize the aqueous solubility of the compound. In certain embodiments, L' is a heteroalkylene moiety. In some other certain embodiments, L' includes an alkylene oxide or phosphodiester moiety, or a combination thereof.
[0061] In certain embodiments, L' has the structure: [ka] (In the formula, m" and n" are independently an integer from 1 to 10; R e is H, an electron pair or a counterion, L” is R e or Q is a direct bond or linking group to a targeting moiety, an analyte molecule (e.g., an analyte molecule), a solid support, a solid support moiety, a nucleoside, or an additional compound of structure (I). has.
[0062] In some embodiments, m" is an integer from 4 to 10, e.g., 4, 6, or 10. In other embodiments, n" is an integer from 3 to 6, e.g., 3, 4, 5, or 6. In some embodiments, n" is an integer from 18 to 28, e.g., 21 to 23.
[0063] In certain other embodiments, L" is an alkylene, alkyleneheterocyclylene, alkyleneheterocyclylenealkylene, alkylenecyclylene, alkylenecyclylenealkylene, heteroalkylene, heteroalkyleneheterocyclylene, heteroalkyleneheterocyclyleneheteroalkylene, heteroalkylenecyclylene, or heteroalkylenecycleneheteroalkylene moiety. In certain other embodiments, L" comprises an alkylene oxide, phosphodiester moiety, sulfhydryl, disulfide, or maleimide moiety, or a combination thereof. In certain of the above-described embodiments, the targeting moiety is an antibody or a cell surface receptor antagonist.
[0064] In other further specific embodiments of any of the compounds of structure (I) above, R 1 or R 2 has the following structure: [ka] has one of the following:
[0065] In other further specific embodiments of any of the compounds of structure (I) above, R 1 or R 2 has the following structure: [ka] has one of the following:
[0066] Certain embodiments of the compounds of structure (I) can be prepared following solid phase synthesis methods similar to those known in the art for the preparation of oligonucleotides. Thus, in some embodiments, L' is a linker to a solid support, a solid support residue, or a nucleoside. Solid supports containing activated deoxythymidine (dT) groups are readily available and can be used, in some embodiments, as starting materials for the preparation of compounds of structure (I). Thus, in some embodiments, R 1 or R 2 has the following structure: [ka] has.
[0067] Those skilled in the art will appreciate that the dT group depicted above is included for ease of synthesis and economic efficiency only, and is not required. Other solid supports can be used, resulting in different nucleosides or solid support moieties being present on L', or the nucleosides or solid support moieties can be removed or modified after synthesis.
[0068] In yet other embodiments, Q, independently at each occurrence, is a moiety that includes a reactive group capable of forming a covalent bond with an analyte molecule or a solid support. In other embodiments, Q, independently at each occurrence, is a moiety that includes a reactive group capable of forming a covalent bond with a complementary reactive group, Q'. For example, in some embodiments, Q' is present in an additional compound of structure (I) (e.g., R 1 or R 2 (positions (I)), Q and Q' contain complementary reactive groups such that reaction of a compound of structure (I) with an additional compound of structure (I) results in a covalent dimerization of the compound of structure (I). Multimeric compounds of structure (I) can also be prepared in an analogous manner and are included within the scope of embodiments of the present disclosure.
[0069] The type of Q group and its attachability to the remainder of the compound of structure (I) are not limited, provided that Q contains a moiety with appropriate reactivity to form the desired bond. In certain embodiments, Q is a moiety that is not susceptible to hydrolysis under aqueous conditions, yet is sufficiently reactive to form a bond with a corresponding group (e.g., an amine, azide, or alkyne) on the analyte molecule or the surface of a solid support. Certain embodiments of the compounds of structure (I) include Q groups commonly used in the field of bioconjugates. For example, in some embodiments, Q includes a nucleophilic reactive group, an electrophilic reactive group, or a cycloaddition reactive group. In some more specific embodiments, Q includes a sulfhydryl, disulfide, activated ester, isothiocyanate, azide, alkyne, alkene, diene, dienophile, acid halide, sulfonyl halide, phosphine, α-haloamide, biotin, amino, or maleimide functionality. In some embodiments, the activated ester is an N-succinimide ester, an imido ester, or a polyflourophenyl ester. In other embodiments, the alkyne is an alkyl azide or an acyl azide.
[0070] Q groups can be conveniently provided in a protected form that enhances storage stability or other desired properties, and then the protected group is removed when appropriate, for example, for conjugation with a targeting moiety or analyte. Thus, Q groups include "protected forms" of reactive groups, including any of the reactive groups listed above and in Table 1 below. A "protected form" of Q refers to a moiety that has a lower reactivity than Q under a given reaction condition, and can be converted to Q under conditions that preferably do not degrade or react with other moieties of the compound of structure (I). Those skilled in the art can derive an appropriate protected form of Q based on the specific Q and the desired end-use and storage conditions. For example, when Q is SH, the protected form of Q includes a disulfide, which can be reduced to reveal the SH moiety using common known techniques and reagents.
[0071] Exemplary Q moieties are provided in Table I below. [Table 1-1] [Table 1-2] [Table 1-3] It should be noted that in some embodiments, when Q is SH, the SH moiety tends to form a disulfide bond with another sulfhydryl group, for example, of another compound of structure (I). Thus, some embodiments include a compound of structure (I) in the form of a disulfide dimer, where the disulfide bond is derived from the Q group that is SH.
[0072] Similarly, compounds of structure (I) are included within the scope of certain embodiments, where R 1 and R 2 One or both of R 1 and R 2 contain a linking group to further compounds of structure (I). For example, R 1 and R 2 One or both of -OP(=R a )(R b )R c and R c is OL', where L' is a linker comprising a covalent bond to a further compound of structure (I). Such compounds can be, for example, those having an "M 1 " portion and / or "M 2 " moieties (i.e., n=10) on a compound of a first structure (I) having a "Q" suitable for reaction with a complementary Q' group on a compound of a second structure (I). In this manner, any number of "M" moieties, e.g., 100 or more, can be prepared. 1 " portion and / or "M 2 Compounds of structure (I) having a "" moiety can be prepared without the need to sequentially couple each monomer. An exemplary embodiment of such a compound of structure (I) is the following structure (I'): [ka] (In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , L 1a , L 1b , L 2, L 3 , L 4 , L 5 , L 6 , L 7 , M 1 , M 1 , q, m, w and n are, at each occurrence, independently, as defined for compounds of structure (I); L″ is a linker that contains a functional group resulting from reaction of a Q moiety with the corresponding Q′ moiety; α is an integer of 1 or more, for example, 1 to 100 or 1 to 10. has.
[0073] Compounds of structure (I') can be derived by one of skill in the art, for example, by dimerizing or polymerizing compounds of structure (I) provided herein.
[0074] In other embodiments, the Q moiety is conveniently masked (e.g., protected) as a disulfide moiety, which can be subsequently reduced to provide an activated Q moiety for conjugation to a desired analyte molecule or targeting moiety. For example, the Q moiety can be a disulfide having the following structure: [ka] where R is an optionally substituted alkyl group. For example, in some embodiments, Q can be masked as a disulfide moiety having the structure: [ka] (wherein n is an integer of 1 to 10). Provided as.
[0075] In some other embodiments, R 1 or R 2 One of the groups is OH or -OP (=R a )(R b )R c and R 1 or R 2The other is a linker that includes a covalent bond to the analyte molecule or a linker that includes a covalent bond to the solid support. For example, in some embodiments, the analyte molecule is a nucleic acid, an amino acid, or a polymer thereof. In other embodiments, the analyte molecule is an enzyme, a receptor, a receptor ligand, an antibody, a glycoprotein, an aptamer, or a prion. In some embodiments, the targeting moiety is an antibody or a cell surface receptor antagonist. In yet another embodiment, the solid support is a polymeric bead or a non-polymeric bead. Fluorescence intensity can also be adjusted by selecting different values of n. In certain embodiments, n is an integer between 1 and 100. In other embodiments, n is an integer between 1 and 10. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10.
[0076] Fluorescence can also be tuned by selecting the value of m. In certain embodiments, m is an integer between 1 and 100. In other embodiments, m is an integer between 7 and 12. In some embodiments, m is an integer between 20 and 26. In some embodiments, m is an integer between 3 and 6. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10. In some embodiments, m is 11.
[0077] M 1 and M. 2 is selected based on the desired optical properties, e.g., based on the desired color and / or fluorescent emission wavelength. In some embodiments, M 1 and M.2 is the same for each occurrence. However, M 1 and M. 2 Each occurrence of 1 and M. 2 and certain embodiments may be 1 and M. 2 It is important to note that M includes compounds that are not the same at each occurrence. For example, in some embodiments, M 1 and M. 2 Each of the molecules is not the same, but has a different M so as to have absorbance and / or emission for use in fluorescence resonance energy transfer (FRET) techniques. 1 Part and M 2 For example, in such embodiments, moieties are selected that are distinct M such that absorbance of radiation at one wavelength causes emission of radiation at a different wavelength by a FRET mechanism. 1 Part and M 2 The portion is selected. 1 Part and M 2 The moiety can be appropriately selected by one of skill in the art based on the desired end use. 1 Part and M 2 Moieties include fluorescein and 5-TAMRA (5-carboxytetramethylrhodamine, succinimidyl ester) dyes.
[0078] M 1 or M 2 are, respectively, M 1 or M 2 The bond may be to the remainder of the molecule from any position (i.e., atom) on the 1 or M 2 to the remainder of the molecule. Exemplary methods include the "click" reaction described herein.
[0079] In some embodiments, M 1 and M. 2is, independently at each occurrence, a fluorescent moiety or a chromogenic moiety. Any fluorescent and / or chromogenic moiety may be used, for example, those known in the art and typically used in colorimetric, UV and / or fluorescent assays. M is useful in various embodiments of the present disclosure. 1 and M. 2 Exemplary moieties include, but are not limited to, xanthene derivatives (e.g., fluorescein, rhodamine, Oregon Green, eosin, or Texas Red); cyanine derivatives (e.g., cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, or merocyanine); squaraine derivatives and ring-substituted squaraines (including seta, setau, and square dyes); naphthalene derivatives (e.g., dansyl and polodan derivatives); coumarin derivatives; oxadiazole derivatives (e.g., pyridyloxazole, nitrobenzoxadiazole, or benzyloxyphenyl benzoate). anthracene derivatives (e.g., anthraquinones, including DRAQ5, DRAQ7, and CyTRAK Orange); pyrene derivatives such as Cascade Blue; oxazine derivatives (e.g., Nile Red, Nile Blue, Cresyl Violet, Oxazine 170); acridine derivatives (e.g., Proflavine, Acridine Orange, Acridine Yellow); arylmethine derivatives: auramine, crystal violet, malachite green; and tetrapyrrole derivatives (e.g., porphine, phthalocyanine, or bilirubin). Other exemplary M 1 and M. 2 Moieties include cyanine dyes, xanthate dyes (eg, Hex, Vic, Nedd, Joe, or Tet); Yakima yellow; Redmond red; Tamura; Texas red, and alexa fluor® dyes.
[0080] In still other embodiments of any of the above, M 1 and M. 2may independently at each occurrence include three or more aryl or heteroaryl rings, or combinations thereof, such as four or more aryl or heteroaryl rings, or combinations thereof, or even five or more aryl or heteroaryl rings, or combinations thereof. 1 and M. 2 independently at each occurrence, contains six aryl or heteroaryl rings, or a combination thereof. In further embodiments, the rings are fused. For example, in some embodiments, M 1 and M. 2 but independently at each occurrence includes three or more fused rings, four or more fused rings, five or more fused rings, or even six or more fused rings.
[0081] In some embodiments, M 1 and M. 2 is, independently at each occurrence, cyclic. For example, in some embodiments, M 1 and M. 2 is, independently at each occurrence, carbocyclic. In other embodiments, M 1 and M. 2 is, independently at each occurrence, heterocyclic. In still other embodiments of the above, M 1 and M. 2 independently at each occurrence, comprises an aryl moiety. In some of these embodiments, the aryl moiety is polycyclic. In other further embodiments, the aryl moiety is a fused polycyclic aryl moiety, e.g., the fused polycyclic aryl moiety may include at least two, at least three, at least four, or even more than four aryl rings. In other embodiments of any of the compounds of structure (I), (Ia), (Ib), (Ic), (Id), (Ie) or (I') above, M 1 Or M 2 independently at each occurrence, contains at least one heteroatom. For example, in some embodiments, the heteroatom is nitrogen, oxygen, or sulfur. In still further embodiments of any of the above, M 1 and M. 2contains, independently at each occurrence, at least one substituent. For example, in some embodiments, the substituent is a fluoro, chloro, bromo, iodo, amino, alkylamino, arylamino, hydroxy, sulfhydryl, alkoxy, aryloxy, phenyl, aryl, methyl, ethyl, propyl, butyl, isopropyl, t-butyl, carboxy, sulfonate, amido, or formyl group.
[0082] In some further more specific embodiments described above, M 1 and M. 2 is independently at each occurrence a dimethylaminostilbene, quinacridone, fluorophenyl-dimethyl-BODIPY, his-fluorophenyl-BODIPY, acridine, terylene, sexiphenyl, porphyrin, benzopyrene (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quaterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9,10-ethynylanthracene, or ter-naphthyl moiety. 1 and M. 2 is independently at each occurrence p-terphenyl, perylene, azobenzene, phenazine, phenanthroline, acridine, thioxanthrene, chrysene, rubrene, coronene, cyanine, perylene imide or perylene amide, or a derivative thereof. 1 and M. 2 is independently at each occurrence a coumarin dye, a resorufin dye, a dipyrrometheneboron difluoride dye, a ruthenium bipyridyl dye, an energy transfer dye, a thiazole orange dye, a polymethine, or an N-aryl-1,8-naphthalimide dye. In still further embodiments of any of the above, M 1 and M. 2 is the same for each occurrence. 1 and M. 2In still more embodiments, one or more of M 1 and M. 2 are the same and one or more M 1 and M. 2 is different.
[0083] In some embodiments, M 1 and M. 2 , independently at each occurrence, is pyrene, perylene, perylene monoimide, or 6-FAM, or a derivative thereof. 1 and M. 2 may, independently for each occurrence, have the structure: [ka] has one of the following:
[0084] M containing a carboxylic acid group 1 Part and M 2 The moiety is in the anionic form (CO 2 - ), but one of skill in the art will appreciate that this will vary with pH and that the protonated form (i.e., -CO 2 It will be appreciated that H) is included in various embodiments. In some specific embodiments, the compound is a compound selected from Table 2. The compounds in Table 2 were prepared according to the procedures described in the Examples, and their identities were confirmed by mass spectrometry.
[0085] [Table 2-1] [Table 2-2] [Table 2-3] As used in Table 2 and throughout this application, R 1 , R 2, n and L′ have the definitions provided for compounds of structure (I) unless otherwise indicated, and F, F′ and F″ are each independently selected from the following structures: [ka] It refers to a fluorescein moiety having the formula: In some embodiments, M 1 or M 2 is, independently at each occurrence, F, F', or F''.
[0086] It is well known in the art that fluorescein moieties tautomerize between quinoid, zwitterionic and lactoid forms. One of skill in the art will readily appreciate that this form is pH dependent, and that each form (e.g., quinoid, zwitterionic and lactoid) is also included within the scope of the embodiments of the present disclosure.
[0087] As used in Table 2 above, and throughout this disclosure, dT refers to the following structure: [ka] (In the formula, R is H or a direct bond.
[0088] As used throughout this disclosure, B and B' refer to the following structures, respectively: [ka] In some embodiments, M 1 or M 2 is, independently at each occurrence, B or B'.
[0089] As used throughout this disclosure, T refers to the following structure: [ka] In a specific embodiment, M 1 or M 2 is T, independently for each occurrence.
[0090] As used throughout this disclosure, C has the following structure: [ka] Refers to... In some embodiments, M 1 or M 2 is, independently for each occurrence, C.
[0091] As used throughout this disclosure, Y has the following structure: [ka] Refers to... In some embodiments, M 1 or M 2 is, independently for each occurrence, Y. Some embodiments include any of those presented in Table 2 and described above, including specific compounds conjugated to a targeting moiety, such as an antibody.
[0092] The present disclosure generally provides compounds that have increased amounts of fluorescence compared to previously known compounds. Thus, certain embodiments provide compounds that have n fluorescent moieties, M 1 and / or M 2 A fluorescent compound comprising: 1 Part or M 2 The present invention is directed to fluorescent compounds that have a peak fluorescence emission that is at least 85% of an emission that is n times higher than the peak fluorescence emission of the moiety, where n is an integer equal to or greater than 2. Fluorescent compounds include compounds that emit a fluorescent signal upon excitation with light, such as ultraviolet light. In some embodiments, the fluorescent compound is a single M 1 Part and / or M 2 The moiety has a peak fluorescence emission that is at least 90% of the n-fold higher emission, 95% of the n-fold higher emission, 97% of the n-fold higher emission, or 99% of the n-fold higher emission than the peak fluorescence emission of the moiety. In some embodiments, n is an integer from 2 to 100, for example, from 2 to 10.
[0093] In some embodiments, n M 1 Part and / or M 2 The moieties may independently have the structure: [ka] (In the formula, [ka] indicates the point of attachment to the fluorescent compound) has one of the following:
[0094] In other embodiments, a single M 1 Part or M 2 The moieties may independently have the structure: [ka] has one of the following:
[0095] In a more specific embodiment, the fluorescent compound has the following structure: [ka] (In the formula, [ka] indicates the point of attachment to the fluorescent compound, and a single M 1 Part or M 2 The moiety has the following structure: [ka] (having n M 1 Part and / or M 2 Includes parts. In another embodiment, the peak fluorescent emission occurs at a wavelength in the range of about 500 to about 550 nm. In further embodiments, the fluorescent compound comprises at least one ethylene oxide moiety. Compositions and analytes comprising any one of the claimed fluorescent compounds are also provided.
[0096] The presently disclosed compounds are "tunable," meaning that one of skill in the art can arrive at a compound with a desired and / or predetermined molar fluorescence (molar brightness) by appropriately selecting the variables in any of the above-mentioned compounds. The "tunability" of the compounds allows the user to easily arrive at a compound with the desired fluorescence and / or color for use in a particular assay or to identify a particular analyte of interest. All variables can affect the molar fluorescence of the compounds, but the M 1 , M 2 , L 1a , L 1b , L 3 , L 4 It is believed that the appropriate selection of q, w, m and n plays an important role in the molar fluorescence of the present compounds. Thus, in one embodiment, a method for obtaining a compound with a desired molar fluorescence comprises: 1 Part or M 2 a step of selecting a portion, M 1 Part or M 2 preparing a compound of structure (I) containing a moiety, and adjusting M to arrive at a desired molar fluorescence. 1 , M 2 , L 1a , L 1b , L 3 , L 4 , q, w, m and n.
[0097] Molar fluorescence can, in certain embodiments, be expressed in terms of the fold increase or decrease compared to the fluorescence emission of the parent fluorophore (e.g., monomer). In some embodiments, the molar fluorescence of the compound is 1.1x, 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x or even greater relative to the parent fluorophore. Various embodiments provide 1 , M 2 , L 1a , L 1b , L 3 , L 4 By appropriate selection of q, w, m and n, compounds having a desired fold increase in fluorescence intensity compared to the parent fluorophore are prepared. For ease of illustration, various compounds that contain phosphorus moieties (e.g., phosphate, etc.) can be used in an anionic state (e.g., -OPO(OH)O - , -OPO 3 2- ) as a charge. One of ordinary skill in the art will readily appreciate that the charge is pH dependent, and that uncharged (e.g., protonated or salts such as sodium or other cations) forms are also included within the scope of embodiments of the present disclosure. Compositions comprising any of the above-mentioned compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other embodiments. In some embodiments, the use of such compositions in analytical methods for detecting one or more analyte molecules is also provided.
[0098] In yet other embodiments, the compounds are useful in a variety of analytical methods. For example, in certain embodiments, the present disclosure provides a method of staining a sample, comprising administering to the sample, for example, R 1 or R 2 is a linker comprising a covalent bond to an analyte molecule (e.g., a biomolecule) or a microparticle, and R 1 or R 2 The other is H, OH, alkyl, alkoxy, alkyl ether or -OP(=R a )(R b )R cin an amount sufficient to produce an optical response when the sample is illuminated at an appropriate wavelength. In some embodiments of the above-described method, R 1 is a linker that includes a covalent linking group to an analyte molecule, such as a biomolecule. For example, in some embodiments, the biomolecule is a nucleic acid, an amino acid, or a polymer thereof (e.g., a polynucleotide or a polypeptide). In even more embodiments, the biomolecule is an enzyme, a receptor, a receptor ligand, an antibody, a glycoprotein, an aptamer, or a prion. In yet another embodiment of the above method, R 1 is a linker that includes a covalent attachment group to a solid support, such as a microparticle. For example, in some embodiments, the microparticle is a polymeric or non-polymeric bead.
[0099] In even more embodiments, the optical response is a fluorescence response. In other embodiments, the sample comprises cells, and some embodiments further comprise observing the cells by flow cytometry. In even more embodiments, the method further comprises distinguishing the fluorescent response from a fluorescent response of a second fluorophore having detectably different optical properties. In another embodiment, the present disclosure provides a method for visually detecting an analyte molecule, such as a biomolecule, comprising: (a) For example, R 1 or R 2 is a linker that contains a covalent bond to the analyte molecule, R 1 or R 2 The other is H, OH, alkyl, alkoxy, alkyl ether or -OP(=R a )(R b )R c providing a compound of structure (I), (b) detecting said compound by its visible properties. The present invention provides a method comprising: In some embodiments, the analyte molecule is a nucleic acid, an amino acid, or a polymer thereof (e.g., a polynucleotide or a polypeptide). In even more embodiments, the analyte molecule is an enzyme, a receptor, a receptor ligand, an antibody, a glycoprotein, an aptamer, or a prion.
[0100] In another embodiment, (a) mixing any of the compounds described above with one or more analyte molecules; and (b) detecting said compound by its visible properties. A method for visually detecting an analyte molecule, such as a biomolecule, is provided, comprising: In another embodiment, there is provided a method for visually detecting an analyte molecule, comprising: (a)R 1 or R 2 mixing a compound of structure (I), where is Q, or a linker comprising a covalent bond to Q, with an analyte molecule; (b) forming a conjugate of the compound and an analyte molecule; and (c) detecting the conjugate by its visible properties. A method is provided that includes:
[0101] Another exemplary method is a method for detecting an analyte, comprising: (a)R 1 or R 2 providing a compound of structure (I), wherein the compound comprises a linker comprising a covalent bond to a targeting moiety having specificity for an analyte; (b) mixing the compound and the analyte, thereby causing association of the targeting moiety with the analyte; and (c) detecting the compound, for example by its visible or fluorescent properties. The present invention includes a method comprising the steps of: In certain embodiments of the above-mentioned method, the analyte is a particle such as a cell, and the method includes the use of flow cytometry.For example, the compound can be provided with a targeting moiety such as an antibody to selectively associate with the desired cell, thus making the cell detectable by any number of techniques, such as visual detection or fluorescence detection.The appropriate antibody can be selected by those skilled in the art depending on the desired end use.The exemplary antibodies used in certain embodiments include UCHT1 and MOPC-21.
[0102] Thus, embodiments of the present compounds find use in any number of methods, including, but not limited to: cell counting, cell sorting, biomarker detection, quantification of apoptosis, determining cell viability, identifying cell surface antigens, determining total DNA and / or RNA content, identifying specific nucleic acid sequences (e.g., as nucleic acid probes), and diagnosing diseases such as hematological cancers.
[0103] In addition to the methods described above, embodiments of the compounds of structure (I) may be used in a variety of applications, including, but not limited to, imaging in endoscopic procedures to identify cancerous and other tissues; single cell and / or single molecule analytical methods, e.g., detection of polynucleotides with little or no amplification; cancer imaging, e.g., by including a targeting moiety in the compound of structure (I), such as an antibody or sugar, or other moiety that preferentially binds to cancer cells; imaging in surgery; histone binding to identify various diseases; e.g., M in the compound of structure (I) 1 Part or M 2 The compounds of structure (I) find utility in a variety of fields and methods, including drug delivery by replacing a moiety with an active drug moiety; and / or as contrast agents in dental work, and other procedures, for example, by preferential binding of the compounds of structure (I) to various microflora and / or organisms.
[0104] Any of the embodiments of the compound of structure (I) described above, as well as any of the variable factors R 1 , R 2 , R3 , R 4 , R 5 , L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , M 1 , M 2 It is understood that any particular option described herein with respect to q, w, m and / or n may be independently combined with other embodiments and / or variables of the compounds of structure (I) to form embodiments of the disclosure not specifically described above. Additionally, the list of options may be combined with any particular variable R in a particular embodiment and / or claim. 1 , R 2 , R 3 , R 4 , R 5 , L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , M 1 , M 2 , q, w, m and / or n, it is understood that each individual option may be deleted from a particular embodiment and / or claim, and that the remaining listing of options is considered to be within the scope of the present disclosure. It is understood that in this description, combinations of substituents and / or variables of the depicted formulae are permissible only if such contributions result in stable compounds.
[0105] It will also be appreciated by those skilled in the art that in the methods described herein, functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include -C(O)-R" (wherein R" is alkyl, aryl or arylalkyl), p-methoxybenzyl, trityl, and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. Protecting groups can be added or removed in accordance with standard techniques known to those skilled in the art and described herein. The use of protecting groups is described in detail in Green, TW and PGM Wutz, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley. As will be appreciated by those skilled in the art, the protecting group may also be a polymeric resin, such as a Wang resin, a Rink resin, or a 2-chlorotrityl chloride resin. Additionally, all compounds of the present disclosure that exist in a free base or acid form can be converted to their salts by treatment with an appropriate inorganic or organic base or acid by methods known to those of skill in the art. Salts of compounds of the present disclosure can be converted to their free base or acid form by standard techniques.
[0106] The following reaction schemes illustrate exemplary methods for making the compounds of the present disclosure. It is understood that those skilled in the art may be able to make these compounds by similar methods or by combining other methods known to those skilled in the art. It is also understood that those skilled in the art may be able to make other compounds of structure (I) that are not specifically exemplified below by similar methods described below, by using appropriate starting components and modifying the parameters of synthesis as necessary. In general, starting components can be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI and Fluorochem USA, or can be synthesized according to sources known to those skilled in the art (see, for example, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)), or can be prepared as described in the present disclosure.
[0107] Reaction Scheme I [ka]
[0108] Reaction Scheme I illustrates methods for preparing intermediates useful in the preparation of compounds of structure (I). 1a , L 1b , L 1b ', L 2 , L 3 , G 1 and M. 1 is as defined above, and R 1 and R 2
[0036] Referring to Reaction Scheme I, in which R is as defined above or a protected variant thereof, compounds of structure a, which can be purchased or prepared by well-known techniques, can be prepared by MG 1 ' gives the compound of structure b, where G 1and G 1 G′ represents a functional group with complementary reactivity (i.e., a functional group that reacts to form a covalent bond). 1 ' is M 1 or M 1 It can be part of the structural backbone of G 1 and G 1 M′ can be any number of functional groups described herein, such as alkynes and azides, respectively, amines and activated esters, respectively, or amines and isothiocyanates, respectively. 2 can be coupled to form compounds of structure (I) in an analogous manner by selecting the appropriate reagents in accordance with Reaction Scheme I above.
[0109] Additionally, compounds of the present disclosure can be prepared according to the methods described in PCT Publication Nos. WO2016 / 183185, WO2017 / 173355, and WO2017 / 177065, each of which is incorporated herein by reference.
[0110] Compounds of structure (I) can be prepared from structure b by synthesis of the following structure (c): [ka] (wherein L is an optional linker, e.g., L 4 ) is) In some embodiments of (c), L can be prepared by reaction with a phosphoramidite compound having the following structure: [ka] (In the formula, L 1a , L 1b , L 1b’ , L 2 , L 3 , L 5 , L 6 , L 7 , L 7 ', G 1 , G2 , M 2 and M. 1 is as defined herein). DNA synthesis methods are well known in the art. Briefly, two alcohol groups, such as R in intermediate b above, 1 and R 2 are functionalized with a dimethoxytrityl (DMT) group and a 2-cyanoethyl-N,N-diisopropylamino phosphoramidite group, respectively. The phosphoramidite group is usually coupled with an alcohol group in the presence of an activating agent such as tetrazole, followed by oxidation of the phosphorus atom with iodine. The dimethoxytrityl group can be removed with an acid (e.g., chloroacetic acid), exposing the free alcohol, which can be reacted with the phosphoramidite group. The 2-cyanoethyl group can be removed after oligomerization by treatment with aqueous ammonia.
[0111] The preparation of phosphoramidites used in oligomerization methods is also well known in the art. For example, primary alcohols (e.g., R 1 ) can be protected as a DMT group by reaction with DMT-Cl. A secondary alcohol (e.g., R 2 ) is functionalized as a phosphoramidite by reaction with a suitable reagent such as 2-cyanoethyl N,N-diisopropylchlorophosphoramidite. Methods for the preparation of phosphoramidites and their oligomerization are well known in the art and are described in further detail in the Examples.
[0112] Compounds of structure (I) are prepared by oligomerization of intermediates b and c according to the well-known phosphoramidite chemistry described above. The phosphoramidite coupling is repeated as many times as desired to incorporate the desired number of repeat units, n, into the molecule. It will be appreciated that compounds of structure (II) can be prepared by analogous methods, as described below. In various other embodiments, compounds useful for the preparation of compounds of structure (I) are provided. The compounds can be prepared in monomeric, dimeric and / or oligomeric forms as described above, and then reacted with M 1 and / or M 2 The moiety is covalently attached to the compound by any number of synthetic methods (eg, the "click" reaction described above) to form a compound of structure (I). Thus, in various embodiments, a compound having the following structure (II): [ka] or a stereoisomer, salt or tautomer thereof, G 1 and G 2 is, independently at each occurrence, a moiety that contains a reactive group, or a protecting analog thereof, capable of forming a covalent bond with a complementary reactive group; L 1a is, independently at each occurrence, a heteroarylene linker; L 1b’ , L 2 , L 3 , L 5 , L 6 and L 7’ is independently at each occurrence an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; L 4 is independently at each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; R 1 and R 2 are each independently H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, -OP(=R a )(R b )R c , Q or a protected form thereof, or L′; R 3 is independently at each occurrence H, alkyl or alkoxy; R4 are independently represented by OH, SH, and O for each occurrence. - , S - , OR d or S.R. d and R 5 is independently at each occurrence oxo, thioxo, or absent; R a is O or S, R b OH, SH, O - , S - , OR d or S.R. d and R c OH, SH, O - , S - , OR d , O.L.', S.R. d , alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, or thiophosphoalkyl ether; R d is the counter ion, Q is, independently at each occurrence, a moiety that contains a reactive group or a protected form thereof that is capable of forming a covalent bond with an analyte molecule, a targeting moiety, a solid support, or a complementary reactive group Q'; L' is, independently at each occurrence, a linker that includes a covalent bond to Q, a linker that includes a covalent bond to a targeting moiety, a linker that includes a covalent bond to an analyte molecule, a linker that includes a covalent bond to a solid support, a linker that includes a covalent bond to a solid support moiety, a linker that includes a covalent bond to a nucleoside, or a linker that includes a covalent bond to an additional compound of structure (I); m, for each occurrence, is an integer greater than 1; n is an integer equal to or greater than 1, q and w are, independently at each occurrence, 0 or 1, provided that at least one occurrence of w is 1. In some embodiments, q is 0.
[0113] In some embodiments of compound (II), L 1a is one of the following structures: [ka] has.
[0114] In some more specific embodiments, the compound has the following structure (IIa): [ka] has.
[0115] In some related embodiments, the compound has one of the following structures (IIb) or (IIc): [ka] (In the formula, L 1b’ is independently at each occurrence an optionally substituted alkylene or an optionally substituted heteroalkylene linker. In some embodiments, L 1b’ is an optionally substituted heteroalkenylene linker.
[0116] In certain embodiments, the compound has one of the following structures (IId) or (IIe): [ka] (In the formula, z is an integer from 1 to 100. has.
[0117] In certain embodiments, L 1b’ has the following structure: [ka] has one of the following: In some specific embodiments, L 1b’is alkylene, for example ethylene, propylene, butylene or pentylene.
[0118] In certain related embodiments, -L 1b’ -G 1 has the following structure: [ka] has one of the following:
[0119] In another embodiment of structure (II), G 1 and G 2 is, independently at each occurrence, a moiety that contains a reactive group capable of forming a covalent bond with a complementary reactive group. G in the compound of structure (II) 1 and G 2 The part is M 1 and / or M 2 The complementary group on the G moiety can be selected from any moiety that has a suitable reactive group for forming a covalent bond with a complementary group on the G moiety. 1 and G 2 The moiety can be selected from any of the Q moieties described herein, including those specific examples provided in Table 1. In some embodiments, G 1 and G 2 Each occurrence independently contains moieties suitable for reactions including copper-catalyzed reactions of azides with alkynes to form triazoles (Huisgen 1,3-dipolar cycloaddition), reactions of dienes with dienophiles (Diels-Alder), strain-promoted alkyne-nitrone cycloaddition, reactions of strained alkenes with azides, tetrazines, or tetrazoles, [3+2] cycloadditions of alkenes with azides, inverse demand Diels-Alder of alkenes with tetrazines, photoreactions of alkenes with tetrazoles, as well as a variety of substitution reactions such as replacement of leaving groups by nucleophilic attack on an electrophilic atom. In some embodiments, G 1 and G 2is independently at each occurrence a moiety that includes an aldehyde, oxime, hydrazone, alkyne, amine, azide, acyl azide, acyl halide, nitrile, nitrone, sulfhydryl, disulfide, sulfonyl halide, isothiocyanate, imidoester, activated ester, ketone, α,β-unsaturated carbonyl, alkene, maleimide, α-haloimide, epoxide, aziridine, tetrazine, tetrazole, phosphine, biotin, or thiirane functional group. 1 or G 2 At least one of G has a structure selected from Table 1. In some more specific embodiments, G 1 or G 2 has, independently at each occurrence, a structure selected from Table 1. In another embodiment, G 1 and G 2 In another embodiment, G 1 and G 2 At each occurrence, independently, G comprises an amino group, an isothiocyanate group, or an activated ester group. 1 and G 2 independently at each occurrence, comprises a reactive group that can react with a complementary reactive group to form a functional group that comprises an alkene, ester, amide, thioester, disulfide, carbocyclic, heterocyclic, or heteroaryl group. For example, in some embodiments, heteroaryl is triazolyl.
[0120] In any other of the above-described embodiments of structure (II), G 1 and G 2 is expressed independently for each occurrence as [ka] It is.
[0121] In some embodiments, the occurring G 1 or G 2 At least one of the following structures: [ka] has one of the following: In some related embodiments, G 1 or G 2 may, independently for each occurrence, have the structure: [ka] has one of the following:
[0122] In some embodiments of compound (II), the occurring G 1 At least one of [ka] In a more specific embodiment, G 1 is expressed independently for each occurrence as [ka] It is. In some embodiments of compound (II), the occurring G 1 or G 2 At least one of the following is -NH 2 In some embodiments, G 1 and G 2 may, in each occurrence, independently represent -NH 2 In certain embodiments, G 1 and G 2 is independently for each occurrence -NH 2 It is. In some embodiments of compound (II), the occurring G 1 and G 2 At least one of G is a protected form of an amine. 1 and G 2 is, in each occurrence, independently a protected form of an amine. In certain embodiments, G 1 and G 2 is independently at each occurrence a protected form of an amine.
[0123] In some of the above embodiments, the protected form of the amine is a trifluoroacetate protected amine. In some embodiments, the protected form of the amine is a BOC protected amine. In some embodiments, the protected form of the amine is an Fmoc protected amine. For example, in certain embodiments, the protected form of the amine is a trifluoroacetate protected amine. 1 or G 2 At least one of the following structures: [ka] has one of the following: In a more specific embodiment, G 1 or G 2 may, independently for each occurrence, have the structure: [ka] has one of the following: In some embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , L 2 , L 3 , L 4 , L 5 or L 6 is as defined in any one of the above embodiments. For example, in some embodiments of compound (II), R 4 Each occurrence of R is oxo. In some embodiments of compound (II), R 5 are independently expressed as OH, O - OR d In certain embodiments of compound (II), L 2 is absent at each occurrence. In some specific embodiments of compound (II), L 3 Each occurrence of is an alkylene linker (e.g., methylene).
[0124] In some embodiments, the compound of structure (II) is a compound of Table 3. [Table 3-1] [Table 3-2] [Table 3-3]
[0125] As detailed above, the compounds of structure (I) and (II) can be prepared by oligomerization using the well-known phosphoramidite chemistry. The applicants have discovered intermediate compounds useful in the synthesis of the compounds of structure (I) and (II). Thus, one embodiment is a compound having the following structure (III): [ka] (In the formula, n 1 is an integer from 1 to 6, n 2 is an integer from 1 to 3, X is O or a direct bond; R 1 '' and R 2 '' is independently at each occurrence H, a protecting group, or an activated phosphorus moiety; R 3 '' is H or alkyl, R 4 '' is alkoxy, haloalkyl, alkyl, optionally substituted aryl or optionally substituted aralkyl) to provide. In some embodiments of compound (III), n 1 In some embodiments, n is 2. In some related embodiments, n is 4. 2 is 1. In certain embodiments, n 1 is 2, and n 2 is 1. In other embodiments, n 1 is 4, and n 2 is 1. In some of the above embodiments, X is a direct bond. In some embodiments of compound (III), n 1is 2. In certain related embodiments, n 2 is 2. In some of the above embodiments, X is O. In some embodiments of compound (III), X is a direct bond. In some embodiments, X is O. In some embodiments of compound (III), R 1 " is H. In certain embodiments, the protecting group is, for example, a trityl protecting group. In some embodiments, R 1 In some embodiments, R'' is trityl. 1 In a more specific embodiment, R 1 '' is 4,4'-dimethoxytrityl.
[0126] In some embodiments, R 2 " is H. In some embodiments, R 2 " is an activated phosphorus moiety. For example, in some embodiments, R 2 '' has the following structure: [ka] (In the formula, R 5 '' is H or cyanoalkyl, R 6 '' is, independently for each occurrence, C 1 -C 6 (It is alkyl) Includes. In some embodiments of compound (III), R 5 In another embodiment, R 5 '' is 2-cyanoethyl. In some embodiments, the R 6 At least one of R '' is isopropyl. 6 '' at each occurrence is isopropyl.
[0127] In certain particular embodiments, R 2 '' has the following structure: [ka] In some embodiments of compound (III), R 3 '' is H. In some embodiments of compound (III), R 4 '' is an aryl containing one, two or three aromatic rings, e.g., R 4 In some embodiments, R'' contains one or two aromatic rings. 4 In some embodiments, R 4 '' is C 1 -C 4 In a more specific embodiment, R 4 '' is -CF 3 In some embodiments, R 4 '' is C 1 -C 4 In a more specific embodiment, R 4 '' is tert-butoxy.
[0128] In some specific embodiments, compound (III) is selected from Table 4. [Table 4] The following examples are offered for purposes of illustration and not limitation. EXAMPLES
[0129] General method Mass spectral analysis was performed on a Waters / Micromass Quattro micro MS / MS system (MS mode only) using MassLynx 4.1 acquisition software. The mobile phase used for LC / MS for the dyes was 100 mM 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), 8.6 mM triethylamine (TEA), pH 8. The phosphoramidites and precursor molecules were also analyzed using a Waters Acquity UHPLC system equipped with a 2.1 mm x 50 mm Acquity BEH-C18 column maintained at 45 °C using an acetonitrile / water mobile phase gradient. Molecular weights of monomer intermediates were obtained using a Waters / Micromass Quattro micro MS / MS system (MS mode only) using tropylium positive ion injection enhanced ionization. Excitation and emission profile experiments were recorded on a Cary Eclipse spectrophotometer. All reactions were carried out in oven-dried glassware under a nitrogen atmosphere unless otherwise noted. Commercial DNA synthesis reagents were purchased from Glen Research (Sterling, VA). Anhydrous pyridine, toluene, dichloromethane, diisopropylethylamine, triethylamine, acetic acid, pyridine and THF were purchased from Aldrich. All other chemicals were purchased from Aldrich or TCI and used as received without further purification.
[0130] Example 1 Synthesis of Compound I-1 Preparation of storage solutions Borate buffer prepared at 250 mM, pH 10 Fluorscein-NHS solution prepared at 350 mM (300 mg in 1.35 mL of 25:75 DMSO:acetonitrile) solid phase synthesis Compound I-1 was prepared on a DNA synthesizer using standard DNA synthesis techniques (i.e., DMT-protected 2-cyanoethyl phosphoramidite) on a solid support. The polymer was removed from the solid support with ammonium hydroxide and lyophilized to a paste. An aliquot of 250 mg was reconstituted in water. Smaller aliquots were removed and serial dilutions were made with 100 mM NaCO at pH 9. 3 and the concentration was determined (A263 ε=10,000). The concentration of the final stock solution was found to be 14.5 mM. Dye Coupling Reaction In a 50 mL centrifuge tube equipped with a magnetic stir bar, water (1.110 μL), borate buffer (1.800 μL), compound I-1 polymer solution (466 μL), acetonitrile (137.5 μL), triethylamine (313 μL), and fluorescein-NHS solution (675 μL) were added. The tube was wrapped in aluminum foil, and the mixture was stirred at room temperature overnight. Size Exclusion Filtration To an Amicon Ultra-15 centrifuge filter (Millipore UFC900324, MW cutoff=3000) was added 1 mL of water. The crude reaction mixture from the dye coupling reaction (4.5 mL) was added to the filtration apparatus. The reaction vessel was rinsed 2× with 4 mL of 100 mM NaOH and the rinse was transferred to the filtration apparatus. The filtration apparatus was centrifuged at maximum speed (3220 g, swinging bucket, 30 min). The filtrate was removed and the retentate was treated with an additional 10 mL of 100 mM NaOH. The filtration apparatus was centrifuged as above. Again, the filtrate was removed and a third 10 mL aliquot of 100 mM NaOH was added to the retentate. The apparatus was centrifuged as above and the filtrate was removed. A fourth 10 mL aliquot of 100 mM NaOH was added to the retentate and centrifuged as above. The filtrate was removed and 10 mL of water was added to the filtrate apparatus. The mixture was centrifuged as above. The retentate was removed, the filtrate container was washed with water, and rinse was added to the final volume (3.5 mL). The desired product was confirmed by LC-MS and the concentration was determined using absorbance. A sample of compound I-1 was also analyzed by PAGE (Figure 1). Figure 1 shows compound A (MW=14104), compound B (MW=15686), and compound C (MW=16231) in comparison to compound I-2.
[0131] Example 2 Synthesis of Compound I-2 Storage solution The borate buffer was prepared as described in Example 1. 4.6M Magnesium chloride A 300 mM fluorescein-NHS solution was prepared in DMSO. solid phase synthesis Compound I-2 was prepared on a DNA synthesizer using standard DNA synthesis techniques (i.e., DMT-protected 2-cyanoethyl phosphoramidite) on a solid support. The polymer was removed from the solid support with concentrated ammonium hydroxide and lyophilized to a paste. 20 mg was reconstituted in water, small aliquots were removed, and serial dilutions were made in 100 mM NaCO. 3The solution was prepared in 50 ml of 1000 ml of water at pH 9 and the concentration was determined (A263 ε=10,000). The concentration of the final stock solution was found to be 11.6 mM. Dye Coupling Reaction In a 200 μL microcentrifuge tube, water (10 μL), borate buffer (20 μL), compound I-2 polymer solution (2.2 μL), magnesium chloride solution (5.4 μL), DMSO (6.9 μL), and fluorescein-NHS solution (5.6 μL) were added. The tube was vortexed and left overnight. The mixture was diluted with 50 mL of water and desalted using a polyacrylamide desalting column (Pierce, Cat. No. 89849). The desired product was confirmed by LC-MS and analyzed by PAGE (Figure 2). Figure 2 shows compound A (MW=14104), compound B (MW=15686), and compound C (MW=16231) in comparison to compound I-2.
[0132] Example 3 Flow Cytometry Methods and Uses A typical flow cytometry workflow involves the following steps: 1. Culture and visually observe cells for signs of metabolic stress and / or use fresh inducer or stimulator cells. 2. Dilute dye compound to working volume. 3. Cells that did not die or undergo apoptosis are harvested and prepared. 4. Centrifuge the cells and wash with an appropriate buffer. 5. Perform cell counts using a hemocytometer and trypan blue exclusion. 6. Centrifuge and wash the cells. 7. Adjust cell density to test size. 8. Apply dye (before dilution) or other co-dye of interest. 9. Incubate the cell / dye / dye mixture. 10. Wash the cells by centrifugation with an appropriate buffer. 11. Resuspend cells in acquisition buffer. 12. Acquire cell data by flow cytometry.
[0133] The general workflow described above can be modified for specific applications. Some modifications for specific applications are described below. Distinguishing between alive and dead To compare damaged and intact cells, cell viability is tested by positively staining necrotic cells. Assays are used that target non-intact (fixed and unfixed) cells with positively charged moieties, cell debris, apoptotic bodies, depolarized cell membranes and permeabilized membranes. Then, using routine cell preparation (fresh or fixed), cells are stained with dyes (e.g., compound I-1) and analyzed using flow cytometry. Cellular Health Comparisons are made between dead cells (i.e. necrotic cells), early apoptotic cells, late apoptotic cells and live cells. Dead cells stain positively, apoptotic bodies stain intermediately and live cells remain negative. This strategy results in necrotic cells that are very bright and also serves to assess cell permeability. Assays are used that target non-intact (fixed and unfixed) cells with positively charged moieties, cell debris, apoptotic bodies, depolarized cell membranes and permeable membranes. In vitro cultures, primary cells and samples treated with xenobiotics are stained with dyes and analyzed using flow cytometry. cell cycle Cell ploidy and mitosis in the cell cycle are tracked by dyes related to positively staining DNA intercalators in all cells and in the cell body containing nucleic acids and cell cycle related proteins. Assays are used that target non-intact (unfixed only) cells with positively charged moieties, cell debris, apoptotic bodies, depolarized cell membranes and permeabilized membranes. Assays are used that target intact (fixed and permeabilized) cells by staining positively charged moieties after fixing and permeabilizing cell pools for intracellular staining. Dye staining (combined with other dyes) is performed on in vitro cultures, primary cells and xenobiotic treated samples and analyzed using flow cytometry. Proliferation Cell proliferation is monitored by dyes associated with positively staining DNA intercalators in all cells and in cell bodies containing nucleic acids and cell cycle-related proteins. Assays are used that target non-intact (only unfixed) cells with positively charged moieties, cell debris, apoptotic bodies, depolarized cell membranes and permeabilized membranes. For intracellular staining, assays are used that target intact (fixed and permeabilized) cells by staining positively charged moieties after fixing and permeabilizing cell pools. In vitro cultures, primary cells and xenobiotic-treated samples are stained with dyes (combined with monitoring markers for cell proliferation, e.g. Ki67, BRDU) and analyzed using flow cytometry.
[0134] Example 4 Activation and antibody conjugation of compound I-1 [ka] Maleimide-functionalized compound I-1 is prepared according to the method described in Example 1. In parallel, UCHT-1 antibody is treated with bis-maleimidoethane ("BMOE") to reduce disulfide bonds. The reduced antibody is reacted with compound I-1 at a polymer to antibody molar ratio of 5:1. This reaction results in a final product with up to a 1:1 polymer to antibody ratio, as detected by size exclusion chromatography.
[0135] All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification, including U.S. Provisional Patent Application No. 62 / 690,656, filed June 27, 2018, are hereby incorporated by reference in their entirety to the extent not inconsistent herewith.
[0136] From the foregoing it will be appreciated that, although specific embodiments of the present disclosure have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the disclosure. Accordingly, the present disclosure is not to be limited except as by the appended claims. Yet another aspect of the present invention may be as follows. [1] A compound having the following structure (I) or a stereoisomer, salt or tautomer thereof: [ka] (In the formula, M 1 and M. 2 is, independently at each occurrence, a moiety that contains a chromophore, L 1a is, independently at each occurrence, a heteroarylene linker; L 1b 、L 2 、L 3 、L 5 、L 6 and L 7 is independently at each occurrence an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; L 4 is independently at each occurrence an alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, or heteroalkynylene linker; R 1 and R 2 are each independently H, OH, SH, alkyl, alkoxy, alkyl ether, heteroalkyl, -OP(=R a )(R b )R c , Q or a protected form thereof, or L′; R 3 is independently at each occurrence H, alkyl or alkoxy; R 4 are independently selected for each occurrence: OH, SH, O - 、S - , OR d or S.R. d and R 5 is independently at each occurrence oxo, thioxo, or absent; R a is O or S, R b OH, SH, O - 、S - , OR d or S.R. d and R c OH, SH, O - 、S - , OR d , O.L.', S.R. d , alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkyl ether, alkoxyalkyl ether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkyl ether, or thiophosphoalkyl ether; R d is the counter ion, Q is, independently at each occurrence, a moiety that contains a reactive group or a protected form thereof that is capable of forming a covalent bond with an analyte molecule, a targeting moiety, a solid support, or a complementary reactive group Q'; L' is, independently at each occurrence, a linker that includes a covalent bond to Q, a linker that includes a covalent bond to a targeting moiety, a linker that includes a covalent bond to an analyte molecule, a linker that includes a covalent bond to a solid support, a linker that includes a covalent bond to a solid support moiety, a linker that includes a covalent bond to a nucleoside, or a linker that includes a covalent bond to an additional compound of structure (I); m, for each occurrence, is an integer greater than or equal to 1; n is an integer equal to or greater than 1, q and w are, independently at each occurrence, 0 or 1, provided that at least one occurrence of w is 1. [2] Appearing L 1a At least one of the above is an optionally substituted 5- to 7-membered heteroarylene linker. 〔3〕L 1a is independently an optionally substituted 5- to 7-membered heteroarylene linker at each occurrence. 〔4〕L 1a is substituted at each occurrence. 〔5〕L 1a is substituted with at least one oxo at each occurrence. [6] Appearing L 1b The compound according to any one of the above [1] to [5], wherein at least one of the following is substituted: 〔7〕L 1b is substituted by oxo. 〔8〕L 1a The compound according to any one of the above items [1] to [7], wherein the compound has one of the following structures:
change
change
[10] Appearing L 3 At least one of the above is an alkylene linker. 〔11〕L 3 is an alkylene linker at each occurrence.
[12] Appearing L 2 The compound according to any one of the above items [1] to
[11] , wherein at least one of the following is absent. 〔13〕L 2 is not present for each occurrence.
[14] Appearing L 5 or L 6 At least one of the following is a heteroalkylene:
[15] Appearing L 4 The compound according to any one of the above items [1] to
[14] , wherein at least one of the above contains an alkylene oxide.
[16] Appearing L 5 or L 6 At least one of the above formula (1) to (15) contains an alkylene oxide.
[17] The compound according to any one of the above
[15] to
[16] , wherein the alkylene oxide is ethylene oxide.
[18] The compound according to
[17] above, wherein the ethylene oxide is polyethylene oxide.
[19] Appearing R 3 At least one of the following is H:
[20] The compound according to any one of the above [1] to
[19] , having one of the following structures (Ib) or (Ic):
change
[21] The compound according to any one of the above [1] to
[20] , having one of the following structures (Id) or (Ie):
change
[22] , 〔24〕R 4 is oxo at each occurrence. 〔25〕R 1 and R 2 are each independently OH or -OP(=R a )(R b )R c The compound according to any one of the above items [1] to
[24] , 〔26〕R 1 or R 2 One of the groups is OH or -OP(=R a )(R b )R c and R 1 or R 2 The compound according to any one of the above [1] to
[24] , wherein the other is Q or a linker containing a covalent bond to Q. 〔27〕R 1 and R 2 However, each is independent of -OP(=R a )(R b )R c The compound according to any one of the above items [1] to
[24] , 〔28〕R c The compound according to any one of the above
[25] to
[27] , wherein is OL'.
[29] The compound according to
[28] , wherein L' is a heteroalkylene linker to Q, a targeting moiety, an analyte molecule, a solid support, a solid support residue, a nucleoside, or a further compound of structure (I).
[30] The compound according to
[29] above, wherein L' comprises an alkylene oxide moiety or a phosphodiester moiety, or a combination thereof.
[31] The compound according to
[30] above, wherein L' has the following structure:
change
[32] The compound according to any one of
[29] to
[31] above, wherein the targeting moiety is an antibody or a cell surface receptor antagonist. 〔33〕R 1 or R 2 The compound according to any one of the above items [1] to
[31] , having one of the following structures:
change
[33] , wherein the compound has the following structure:
change
[35] The compound according to any one of the above [1] to
[31] , wherein Q contains a nucleophilic reactive group, an electrophilic reactive group, or a cycloaddition reactive group.
[36] The compound according to
[35] above, wherein Q comprises a sulfhydryl, disulfide, activated ester, isothiocyanate, azide, alkyne, alkene, diene, dienophile, acid halide, sulfonyl halide, phosphine, α-haloamide, biotin, amino or maleimide functional group.
[37] The compound according to
[36] above, wherein the activated ester is an N-succinimide ester, an imido ester or a polyfluorophenyl ester.
[38] The compound according to
[36] above, wherein the azide is an alkyl azide or an acyl azide.
[39] The compound according to any one of the above [1] to
[31] , wherein Q is a moiety selected from Table 1. 〔40〕R 1 or R 2 One of the groups is OH or -OP(=R a )(R b )R c and R 2 or R 3 The compound according to any one of the above [1] to
[24] , wherein the other linker is a linker comprising a covalent bond to an analyte molecule, a linker comprising a covalent bond to a target moiety, or a linker comprising a covalent bond to a solid support.
[41] The compound according to
[40] above, wherein the analyte molecule is a nucleic acid, an amino acid, or a polymer thereof.
[42] The compound according to
[40] above, wherein the analyte molecule is an enzyme, a receptor, a receptor ligand, an antibody, a glycoprotein, an aptamer or a prion.
[43] The compound according to
[40] above, wherein the targeting moiety is an antibody or a cell surface receptor antagonist.
[44] The compound according to
[40] above, wherein the solid support is a polymeric bead or a non-polymeric bead.
[45] The compound according to any one of the above [1] to
[44] , wherein n is an integer of 1 to 100.
[46] The compound according to any one of the above [1] to
[45] , wherein n is an integer of 1 to 10.
[47] The compound according to any one of the above [1] to
[46] , wherein m is an integer of 7 to 12.
[48] The compound according to any one of the above [1] to
[46] , wherein m is an integer of 3 to 6. 〔49〕M 1 and M. 2 is, independently at each occurrence, a moiety containing four or more aryl rings or heteroaryl rings, or a combination thereof. 〔50〕M 1 Or M 2 is, independently at each occurrence, fluorescent or chromogenic. 〔51〕M 1 and M. 2 The compound according to
[50] above, wherein the compound is fluorescent. 〔52〕M 1 and M. 2 Each occurrence of is independently a fused polycyclic aryl moiety containing at least four fused rings. 〔53〕M 1 and M. 2 is independently at each occurrence a dimethylaminostilbene, quinacridone, fluorophenyl-dimethyl-BODIPY, his-fluorophenyl-BODIPY, acridine, terylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quaterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9,10-ethynylanthracene, or ter-naphthyl moiety. 〔54〕M 1 and M. 2 is independently p-terphenyl, perylene, azobenzene, phenazine, phenanthroline, acridine, thioxanthrene, chrysene, rubrene, coronene, cyanine, perylene imide, perylene amide, or a derivative thereof. 〔55〕M 1 and M. 2 is independently a coumarin dye, a resorufin dye, a dipyrrometheneboron difluoride dye, a ruthenium bipyridyl dye, an energy transfer dye, a thiazole orange dye, a polymethine, or an N-aryl-1,8-naphthalimide dye. 〔56〕M1 and M. 2 is independently at each occurrence pyrene, perylene, perylene monoimide, 6-FAM, or a derivative thereof. 〔57〕M 1 and M. 2 Each occurrence of each of the compounds according to any one of the above [1] to
[52] has one of the following structures:
change
[58] A compound selected from Table 2.
[59] A method for staining a sample, comprising the step of adding to the sample a compound described in any one of [1] to
[58] above in an amount sufficient to produce an optical response when the sample is illuminated with an appropriate wavelength.
[60] The method according to
[59] , wherein the optical response is a fluorescent response.
[61] The method according to any one of
[59] to
[60] above, wherein the sample comprises cells.
[62] The method according to
[61] , further comprising the step of observing the cells by flow cytometry.
[63] The method according to
[62] , further comprising a step of distinguishing the fluorescent response from the fluorescent response of a second fluorophore having detectably different optical properties.
[64] A method for visually detecting an analyte molecule, comprising: (a)R 1 or R 2 is a linker comprising a covalent bond to an analyte molecule; and (b) detecting the compound by its visible properties; The method includes:
[65] A method for visually detecting an analyte molecule, comprising: (a)R 1 or R 2 is Q or a linker containing a covalent bond to Q, mixing the compound according to [1] above with an analyte molecule; (b) forming a conjugate of the compound and the analyte molecule; and (c) detecting the conjugate by its visible properties. The method includes:
[66] A method for visually detecting an analyte, comprising: (a)R 1 or R 2 providing a compound according to any one of the above [1] to
[33] , wherein the compound comprises a linker comprising a covalent bond to a targeting moiety having specificity for an analyte; (b) mixing the compound and the analyte, thereby allowing the targeting moiety to associate with the analyte; and (c) detecting the compound by its visible properties. The method includes:
[67] A composition comprising the compound according to any one of [1] to
[58] above and one or more target molecules.
[68] Use of the composition described in
[67] in an analytical method for detecting one or more analyte molecules.
[69] A compound having the following structure (II), or a stereoisomer, salt, or tautomer thereof:
change
change
[71] The compound according to any one of
[69] or
[70] above, having the following structure (IIa):
change
[72] The compound according to any one of the above
[69] to
[71] , having one of the following structures (IIb) or (IIc):
change
[73] The compound according to any one of the above
[69] to
[72] , having one of the following structures (IId) or (IIe):
change
[74] Appearing G 1 or G 2 The compound according to any one of the above
[69] to
[73] , wherein at least one of the following has a structure selected from Table 1. 〔75〕G 1 or G 2 has a structure independently selected from Table 1 at each occurrence.
[76] Appearing G 1 or G 2 The compound according to any one of the above
[69] to
[75] , wherein at least one of the following structures is present:
change
[69] to
[76] , wherein each occurrence of
change
[78] Appearing G 1 At least one of
change
[69] to
[77] , 〔79〕G 1 But each occurrence is independent.
change
[69] to
[78] , 〔80〕R 1 or R 2 The compound according to any one of the above
[69] to
[79] , wherein is defined by any one of the above
[25] to
[44] . 〔81〕R 4 is oxo at each occurrence. 〔82〕R 5 However, each occurrence is independent, OH, O - OR d The compound according to any one of the above items
[69] to
[81] , 〔83〕L 2 is not present for each occurrence. 〔84〕L 3 is an alkylene linker at each occurrence. 〔85〕L 4 、L 5 or L 6 is as defined in any one of the above items
[14] to
[18] .
[86] A compound having the following structure (III):
change
[86] , wherein "" is H or 4,4'-dimethoxytrityl. 〔88〕R 2 The compound according to any one of the above items
[86] to
[87] , wherein "" is H or has the following structure:
change
[86] to
[88] , wherein "" has the following structure:
change
[86] to
[89] , wherein is 1 and X is a direct bond. 〔91〕n 1 is 2, and n 2 The compound according to any one of the above
[86] to
[89] , wherein is 1 and X is a direct bond. 〔92〕n 1 is 2, and n 2 The compound according to any one of the above
[86] to
[89] , wherein is 2 and X is O. 〔93〕R 3 The compound according to any one of the above items
[86] to
[92] , wherein "" is H. 〔94〕R 4 The compound according to any one of the above items
[86] to
[93] , wherein "" is haloalkyl. 〔95〕R 4 '' but -CF 3 The compound according to any one of the above items
[86] to
[94] , 〔96〕R 4 The compound according to any one of the above items
[86] to
[93] , wherein "" is alkoxy. 〔97〕R 4 The compound according to any one of the above items
[86] to
[93] or
[96] , wherein "" is tert-butoxy.
[98] A compound having structure (III) selected from Table 4.
Claims
1. A compound having the following structure (Ia): or a stereoisomer, salt, or tautomer thereof: (In the formula, M 1 may, independently at each occurrence, have the structure: and L 1a is, independently at each occurrence, a heteroarylene linker; L 1b is independently at each occurrence a heteroalkylene or heteroalkenylene linker; L 2 is not present for each occurrence, L 3 is, at each occurrence, an alkylene linker; L 4 is, independently at each occurrence, an alkylene oxide; R 1 and R 2 are each independently -OP(=R a ) (R b ) R c or L′, R 4 is independently, at each occurrence, OH or O - and R 5 is, independently at each occurrence, oxo; R a is O, R b is OH or O - and R c is OL′, L′, independently at each occurrence, has the structure: (In the formula, m″ and n″ are independently integers from 1 to 10; R e is H, an electron pair or a counterion, L” is R e or a linking group to Q, Q is, independently at each occurrence, a moiety selected from sulfhydryl, disulfide, N-succinimide ester, imidoester, polyfluorophenyl ester, isothiocyanate, azide, alkyne, alkene, diene, dienophile, acid halide, sulfonyl halide, phosphine, α-haloamide, biotin, amino, and maleimide functional groups; m, for each occurrence, is an integer greater than or equal to 1; and n is an integer of 2 or more.
2. (A) Appearing L 1a at least one of is a substituted 5- to 7-membered heteroarylene linker; (B) L 1a is, independently at each occurrence, a substituted 5- to 7-membered heteroarylene linker; (C) L 1a is replaced for each occurrence, or (D) L 1a is substituted for each occurrence by at least one oxo, or (E) L 1a has the following structure: The compound of claim 1 having one of the following:
3. 3. The compound of claim 1 or 2 having one of the following structures: (A) Structure (Ib): Or structure (Ic): (B) Structure (Id): Or structure (Ie): (In the formula, z is an integer from 1 to 100.
4. R 4 However, for each occurrence, - That is, The compound according to claim 3.
5. (A) R 1 Or R 2 has the following structure: or (B) R 1 Or R 2 has the following structure:
4. The compound of claim 3 having the formula:
6. Q is one of the following structures: (In the formula, X is halo, and EWG is an electron withdrawing group. The compound of claim 1 , wherein the moiety has the formula:
7. (A) n is an integer from 2 to 100, (B) n is an integer from 2 to 10, (C) m is an integer from 7 to 12; or (D) m is an integer from 3 to 6 The compound of claim 1.
8. The following structure: (In the formula, F, F', and F" each have the following structure: is a fluorescent moiety having the formula R 2 teeth, and dT is, where R is H or a direct bond. A compound having one of the following:
9. 1. A method for visually detecting an analyte molecule, comprising: (a) R 1 Or R 2 is a linker comprising a covalent bond to an analyte molecule; and (b) detecting the compound by its visible properties The method includes:
10. 1. A method for visually detecting an analyte molecule, comprising: (a) R 1 Or R 2 is a linker comprising a covalent bond to Q, (b) forming a conjugate of the compound and the analyte molecule; and (c) detecting the conjugate by its visible properties The method includes:
11. 1. A method for visually detecting an analyte molecule, comprising: (a) R 1 Or R 2 comprising a linker comprising a covalent bond to a targeting moiety having specificity for an analyte molecule; (b) mixing the compound and the analyte molecule, thereby allowing the targeting moiety to associate with the analyte molecule; and (c) detecting the compound by its visible properties The method includes:
12. A composition for detecting one or more analyte molecules, comprising the compound of claim 1 and one or more analyte molecules.
13. L 1b may, independently at each occurrence, have the structure: The compound of claim 1 having one of the following formulas:
Citation Information
Patent Citations
Fluorescence signal amplification probe intermediate, fluorescent probe and preparation method thereof
CN106589005A
tag library compounds, compositions, kits and methods of use
JP2003532092A
Water-soluble fluorescent dye or colored dye and its use
JP2016534107A
Water-soluble fluorescent or colored dyes containing conjugated groups
JP2018507863A
ultra-bright dimer or polymer dye
JP2018515628A
